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NOTES
1. All the temperatures are expressed in degree centigrade (0C).
2. Melting points of all the compounds are uncorrected and
have been recorded by open capillary method.
3. Room temperature, wherever mentioned, normally corresponds
to 280 to 33 0C.
4. Silica gel-G was used for preparing the TLC plates using
different solvant systems.
5. Infra red spectra  of all the compounds were scanned on
SHIMADZU-FOURIER TRANSFORM INFRA RED
(FT-IR)-8400 Spectrophotometer using KBr disc.
6. PMR Spectra were recorded on BRUKER Spectrophotom-
eter(400 MHz) using TMS as a internal standard and CDCI3
and DMSO-d6 as solvants.
7. 13C NMR Spectra were recorded on BRUKER Spectropho
tometer(400 MHz) using CDCI3,and DMSO-d6 as solvants.
8. MASS spectra were recorded on GC-MS-QC-2010.
ABBREVIATIONS
(1) gl.= glacial.
(2) M.P= Melting point.
(3) B.P= Boiling point.
(4) BP= British pharmacopeis.
(5) DMSO= Dimethyl sulphoxide.
(6) DMSO-d6= Dutereted dimethylsulphoxide.









(14) WHO= World health organization.
(15) E. coli = Escherichia coli.
(16) P. aeruginosa= Pseudomonas aeruginosa.
(17) S. aureus = Staphylococcus aureus.
(18) S.pyogenes = Streptococcus pyogenes.
(19) A. niger = Aspergillus niger.
(20) A. clavatus= Aspergillus clavatus.
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1Synopsis....“ Studies and Biological Evaluation of Synthetic Therapeutic Agents”
   STUDIES AND BIOLOGICAL EVALUATION OF
            SYNTHETIC THERAEUTIC AGENTS
.
A  brief summary of  the work to be incorporated in the thesis entitled,
“ STUDIES AND  BIOLOGICAL EVALUATION OF SYNTHETIC THERAPEUTIC
AGENTS’’ has been summarized as under.
PART-I : STUDIES  ON 1,4-DIHYDRO PYRIDINES
PART-II : STUDIES ON  PHENOTHIAZINES
PART-III : STUDIES ON  PYRIMIDINES
PART-I : STUDIES ON 1,4-DIHYDRO PYRIDINES
1,4-Dihydro pyridines are one of the most active class of compounds
possessing diverse biological activity viz., calcium channel blocker,
cardiovascular, vasodilator, antihypertensive, antitubercular and anti-HIV
activities. Promoted by above facts, these valid observations lead us to
synthesize some novel 1,4-dihydropyridines that have been described as
under.
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4-(5’-Chloro-3’-methyl-1’-N-phenyl-pyrazol-4’-yl)-2,6-dimethyl/-
6isopropyl-3,5-disubstituted phenylcarbamoyl-1,4-dihydropyridines
(Ia-t )  have been prepa- red by the cyclocondensation of one mole of 5-chloro-
3-methyl-1-phenyl-pyrazole-4-carbaldehyde, two moles of N-(substituted
-phenyl)-3-oxobutanamides/4-methyl 3-oxopetanamides and ammonia.
SECTION - II : Preparation and biological evaluation of 4-(5’- Chloro-3’-
  methyl-1’-N-phenyl-pyrazol-4’-yl)-2,6-dimethyl/6-isopropyl-
  2-methyl-3-carbmethoxy/ethoxy-5-substituted phenylcar-
                       bamoyl-1,4-dihydropyridines (IIa-n’).
 R   = substituted phenyl     
 R'  = Methyl/ Isopropyl 











 R = substituted phenyl     
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4-(5’-Chloro-3’-methyl-1’-N-phenyl-pyrazol-4’-yl)-2,6-dimethyl/6-
isopropyl-2-methyl-3-carbmethoxy/ethoxy-5-substituted phenyl-
carbamoyl-1,4-dihydropyridine (IIa-n’) have been prepared by the
condensation of 2-[(5’-chloro-3’-methyl-1’-N-phenyl-pyrazol-4’-yl)-
methylene]-3oxo-N-p-tolylbutanamide and methyl-3-aminobut-2-enoate/
ethyl-3-aminobut-2-enoate in basic mediam.
PART-II : STUDIES ON  PHENTOTHIAZINES DERIVATIVES
       Phenothiazines possess a wide spectrum of pharmacological activites
such as antituberculer, antitumor, anticonvulsant, tranquilizers, antiemetic etc.
N-substituted phenothiazine nucleus causes a marked difference in activities
and therefore phenothiazines with varied substituents has been synthesized
and further their condensation reaction with secondary amine in presence of
formaldehyde has been carried out and tested for activities in search of better
medicinally interested agents.
SECTION - I :Preparation  and biological evaluation of 7/8/9-Substituted
-10-N- [bis (2-chloroethyl/diethyl)-amino]-methyl phenothi








 R = H, o/m/p-CH3,-OCH3 and -NO2      
 R'=  -H/ Cl
(III a-t)
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7/8/9-Substituted 10-N-[bis (2-chloroethyl/diethyl)-amino]-methyl-
phenothiazine-1-carboxylic acids (IIIa-t) have been prepared by the reac-
tion of different substituted phenothizines, dichloroethylamine/diethy-
lamine, and formaldehyde in acidic medium.
SECTION - II : Prepareation and biological evaluation of 7/8/9-Substit-
uted-10-N-[(carboxymethyl)-sulfanylacetyl]-phenothiazine-
1- carboxylic acids (IVa-j).
7/8/9-Substituted-10-N-[(carboxymethyl)-sulfanyl-acetyl]-pheno
thiazines-1-carboxylic acids (IVa-j) have been prepared by the reaction of
different substituted phenothizines,chloroacetylchloride and thiog-
lycollicacid in basic media.
PART-III : STUDIES ON PYRIMIDINES
 Pyrimidines represent one of the most active classes of compounds
possessing a wide spectrum of biological activities viz., significant in vitro
activity against unrelated DNA and RNA viruses including Polio and Herpes
viruses,  diuretics, antitubercular, antihypertensive. Some pyrimidines, which
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occurs as natural products like nucleic acids and vitamin-B and can be used
as therapeutic agents for the treatment of AIDS and antitumor.  In view of getting
better theraputic agents baring pyrimidine nucleus, it was thought worthwhile
to synthesize some newer pyrimidine derivatives which can be summarized
as below.
Section-I :  4-(5’-chloro-3’-methyl-1’-N-phenyl-pyrazol-4’-yl)-6-methyl-2-




pyrimidines (Va-d’)  have been prepared by the reaction of 5-chloro-3-
methyl-1-phenyl-pyrazol-4-carbaldehyde, N-(substituted phenyl)-3-











Where R= substituted phenyl
            X= O/ S/NH
(Va-d' )
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PURIFICATION AND STRUCTURAL CHARACTRISATION:
The purity of all compounds have been screened by thin layer
chromatography using two different solvent systems (Rf1 & Rf2). The
constitution of newly synthesized compounds have been delineated by
elemental analysis, FT-IR, 1H NMR and Mass spectoscopy.
ANTIMICROBIAL ASSAY:
The purified organic compounds have been screened for their in vitro
therapeutic assay like antibacterial activities towards Gram possitive and
Gram negative bacterial strain and antifungal activity towards fungal strain at
different concentrations (Minimum Inhibitory Concentration). The biological
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STUDIES AND BIOLOGICAL EVALUATION OF
SYNTHETIC THERAPEUTIC AGENTS
(A) Drug
The word drug is derived from the French word “drogue” which means
‘a dry herb’. It is the single active chemical entity present in a medicine that
is used for diagnosis, prevention, treatment / cure of a disease. This dis-
ease oriented definition of drug does not include contraceptives or use of
drugs for improvement of health. According to “WHO” a drug may be defined
as “Any  substance or product which is used or intended to be used for modi-
fying or exploring physiological system as pathological status for the benefit
of the recipient”.
(B) Pharmacology
Pharmacology is the science of drugs. In a broad sense, it deals with
interaction of exogenously administered chemical molecules (drugs) with
living system. It encompasses all aspects of knowledge about drugs, but most
importantly those that are relevant to effective and safe use for medicinal
purposes. For thousands of years most drugs were crude natural products of
unknown composition and limited efficiency. Only the over effects of these
substances on the body were rather imprecisely known, but how the same were
produced was entirely unknown. Over the past 100 years or so, drugs have
been purified, chemically characterized and a vast variety of highly potent and
selective new drugs has been developed. The two main divisions of
pharmacology are pharmacodynamics and pharmacokinetics.
(a) Pharmacodynamics : It is derived from the Greek word “dynamic”
means power. What the drugs does to the body? This includes physiologi-
cal and biochemical  ef fects of  drugs and their  mechanism of  act ion
at macromolecular / sub cellular organ systems.
(b) Pharmacokinetics : It is derived from the Greek word ‘Kinesis’
means movement. What the body does to the drug ? This refers to move-
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ments of the drug in and alternation of the drug by the body; includes ab-
sorption, d ist r ibut ion,  b inding /  local izat ion /  s torage,  b iotransforma-
t ion and excretion of the drug.
      Some other important aspects of pharmacology are given as under :
* Pharmacotherapeut ics  :  I t  i s  t he  app l i ca t i on  o f  pha rmaco-
dynamic information together with knowledge of the disease for its
prevention, mitigation or cure.
* Clinical  Pharmacology :  I t  is  the sc ient i f ic  s tudy of  drug in
man. I t  inc ludes pharmacodynamic and pharmacokinet ic  inves
tigation in healthy volunteers and in patients; evaluation of efficiency
and safety  o f  d rugs  and  compara t i ve  t r i a l s  w i th  o the r fo rms
o f  t rea tmen ts ;  surveillance of patterns of drug uses, adverse
effects, etc.
* Chemotherapy : It is the treatment of systemic infection / malignancy
wi th speci f ic  drugs that  have se lect ive tox ic i ty  for  the in fect
ing  organism / malignant cell with less effect on the host cells.
?  Drugs in general, can thus be divided into :
* Pharmacodynamic agents :  These are chemical substances
designed to have pharmacodynamic effect in the recipient.
* Chemotherapeutic agents : These are chemical substances designed
for the treatment of infectious diseases or by the proliferation of malignant cells.
(c) Essential Drug Concept: The ‘WHO’ has defined Essential Drugs
as “those that satisfy the healthcare needs of majority of the population; they
should therefore be available at all times in adequate amounts and in
appropriate dosage form”.
I t  has been real ized that only a handful  of  drugs out of  the
multitude available can meet the health needs of majority of the people in any
country, and that may be well tested and cheaper drugs are equally (or more)
efficient and safe as their newer more expensive congeners. For optimum
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utilization of resources, governments (specially in developing countries) should
concentrate on these drugs by identifying them as Essential Drugs. The “WHO”
has laid down criteria guide selection of an essential drug which are as follow
:
(I) Adequate data on its efficiency and safety should be available from
          clinical studies.
(II) It should be available in a form in which quality, including bioavailability and
stability on storage can be assured.
(III) Its choice should depend upon pattern of prevalent diseases; avail
ability  o f  fac i l i t ies  and t ra ined personne l ;  f inanc ia l  resources;
genet ic ,  demographic and environmental factors.
(IV) In case of two or more similar drugs, choice should be made on the
basis of their relative efficiency, safety, quality, price, availabil ity
and cost benefit ratio should be a major consideration.
(V) Choice may also be influenced by comparative pharmacokinetic proper
ties and local facilities for manufacture and storage.
(VI) Most essential drug should be single compound. Fixed ratio combina
tion products should be included only when dosage of each ingredient
meets the requirements of a defined population group, and when the
combination has a proven advantage.
(VII) Selection of essential drug should be a continuous process which should
take into account the changing priorities for public health action, epide-
miological condition as well as availability of better drugs/ formulations
and progress in pharmacological knowledge.
(C)  Drug Development:
Many natural products by trial and error, came into practise for combat-
ing human ailments existent during early human observation. With the advent
of    modern scientific approach, various plant medicines came under
chemical scrutiny, ultimately leading to the isolation of active principles since
early.
Such compounds either in extract form or in pure form became a part of
pharmacopoeias. For instance, though the Chinese drug, Mauhang was in use
for over 5000 years for the treatment of various types of fever and respiratory
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ailments, its active principle, Ephidrine was isolated in 1887. In 1925 chemi-
cal investigations followed by pharmacological evaluation led this compound
into the modern medicine. Similarly during this period, urea stibamine was
introduced as the first drug in 1920 for the treatment of Kala-azar. In 1930, De
Rauwolfia preparation were first employed for sedative and hypotensive prop-
erties.
A drug is a substance having abnormal effect on certain body functions
eg. Strychnine stimulates the action of heart and aspirin retards its action.
Since both of them effects abnormally, the two substances are known as drugs.
Chemical    sciences contributed extensively new discoveries leading to use-
ful drugs since after 1930. The modern concept of drug discovery started in
1933 by Gerhand Domagk with his finding of “Prontosil Red”, a compound
responsible for the antibacterial activity. The advent of sulphonamides drew
the attention for the different activities of various chemicals for bacterial and
human cells, this important factor prompted Florey and Chain in 1939 to in-
vestigate penicillin which was discovered ten years earlier by Alexander
Fleming. The spectacular chemotherapeutical properties of penicillin and its
dramatic war-time development for the treatment of wounds made penicillin,
a most commonly used inexpensive drug.
           A large number of important drugs have been introduced during the
period of 1940 to 1980. This period is known as “Golden period” of new drug
discovery. Thus starting from 1933 - the first antibacterial drug prontosil lead-
ing to various  sulpha drugs ; 1940 – penicillin ; 1945 – chloroquine – anti-
malarial ; 1950 – Methyldopa – anti-hypertensive; 1967 – chlorothiazine
-diuretic; 1958 - adrenergic beta blockers coronary vasodilatory; 1960 - semi
synthetic penicillin -antibacterial; 1965 -trimethoprim-antimicrobial;1967-
disodium chromoglycoate - antiallergic; 1972 - cimetidine H2– antagonist;
1975 -verapamil- calciumantagonist and 1981 - captopril - antihypertensive.
There are some specific examples representing new therapeuticagent  eg. Metormine
glipizide-anti diabetic.
(D) Latest Drug Developments:
The current interest in the creation of large, searchable libraries of
organic compounds has captured the imagination of organic chemists and
the drug discovery community. In numerous laboratories the Efforts are focused
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on the introduction of chemical diversity, which have been recently reviewed
and pharmacologically interesting compounds have been identified from li-
braries of widely different compositions.
Today, the chief source of agents for the cure, the mitigation or the
prevention of diseases are the organic compounds, natural or synthetic, to-
gether with so-called organometallics. Such agents have their origin in a num-
ber of ways (a) from naturally occurring materials - of both plant and animal
origin, and (b) from the isolation of organic compounds synthesized in labora-
tory whose structures are closely related to those of naturally occurring com-
pounds for eg. atropine, steroids, morphine, cocaine etc. that have been
known to possess useful medicinal properties.
The process of drug design is extensively driven by the instinct  and
experience of pharmaceutical research scientists. It is often instructive to at-
tempt to “capture” these experiences by analyzing the historical record that
are successful drug design projects of the past. From this analysis, the infer-
ences are drawn  which play an important role in shaping our  current and
future projects. Towards this region, we would like to analyse the structures of
a large number of drugs  the ultimate product of a successful drug design ef-
fort. Our goal for this is to  begin to deconvolute this information in order to
apply it to design of new drugs.
Different kinds of drugs are developed for different types of diseases
viz. which can be defined with their names of the modern drugs are as under.
(a) Anticancer drugs:
The drugs, which stops the abnormal growth of cell tissues in human
body, are termed as anticancer drug. Vinblastin and Busulphan are the novel
anticancer drugs.
(b) Hepatoprotective drugs:
Drugs, which gives vitality to liver and protects liver by giving immunity
power against antibodies, are termed as Hepatoprotective drug.
(c) Antimalarial drugs:
Drugs, which kills the plasmodium causing malaria are called antima-
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larial drug. Combination of Sulphamethoxazole with Pyrimethamine is a
novel antimalarial drug.
(d)      Drug for meningitis:
Drugs, which cures the inflammation of meningitis, are termed as
meningitis drugs Cifalexin is a novel meningitis drug.
(e)      Drug for typhoid:
Drugs, which kills the bacteria of Salmonella typhi causing typhoid are
known as typhoid drugs. A novel drug for typhoid is Ciprofloxacin.
(f)       Antidiabetic drugs:
Drugs, which converts the excess glucose of blood into glycogen are
termed as antidiabetic drugs. Novel antidiabetic drugs are Metformin,
Glipizide and Gliclazide.
(g) Antitubercular drugs:
Drugs, which kills the bacteria of mycobacterium tuberculosis and thus
cures lesions of pleural cavity. A novel antitubercular drug is Ethambutol.
(h) Antiasthamatic drugs:
             Drugs, which prevents the attack of asthama and gives relax respira-
tion are called antiasthamatic drugs. Novel antiasthamatic drugs are
Ethophylline, Theophylline and Asmon.
(i) Antihypertensive drugs:
            Drugs, which normalizes the blood pressure by dilating blood vessels
are called antihypertensive drugs. Novel antihypertensive drugs are
Atenolol,  Amlodipine and Nifedipine.
(j)        Anti-AIDS drugs:
          Drugs, which kills the viruses of AIDS i.e., HIV-1 and HIV-2 are called
anti-AIDS drugs. Novel drugs are Zidovudine, Acyclovir and Didanosine.
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(k) Antacid drugs:
           Drugs, which neutralize the acid in stomach and stops excessive
secretion of acid, are called antacid drugs. Novel antacid drugs are
Omeprazole and Lansoprazole.
(l)      Non steroidal antiinflammatory drugs (NSAID):
Drugs, which gives relief from fever, pain and inflammation are called
NSAID. Novel NSAID are Pyroxicam, Meloxicam and Nimesulide.
Different kind of drugs generally used are designed as anaesthetic,
ant i tuberculostat ic,  ant ihypertensive, ant iconvulsant,  anthelmint ic,
antiinflammatory, sedative and hypnotics which prompted us to synthesise
drugs having 1,4-Dihydropyridines, Phenothizines and Pyrimidines moi-
eties as a better therapeutic activity.
? Aims and objectives of the present investigation are
(a) To generate several biologically active heterocyclic moieties such as
14-Dihydropyridines, Phenothiazines and Pyrimidines.
(b) To characterize these products for their structural assignment using
various spectroscopic techniques like IR, PMR and Mass spectroscopy.
(c) To screen these purified new derivatives for their antimicrobial activity
using      different st ra ins of  bacter ia and fungi  and to compare ant imi-
crobia l  act iv i ty  against different known drugs at different concentrations for
their MIC values.
In view of these facts, the research work presented in thesis are as fol-
lows.
( I )   STUDIES ON  1,4-DIHYDROPYRIDINES
( II )   STUDIES ON PHENOTHIAZINES











In 1,4-dihydropyridine structure either imino (NH) or substituted nitro-
gen atom is present at the  one position and hydrogen atom at the four posi-
tion of the six membered heterocyclic ring which can be represented as under
(1).
  R1, R4  = H / Alkyl / Aryl
   R2, R6  = Methyl, Isopropyl
   R3, R5  =  Acetyl /Carbmethoxy/
     Carbethoxy / N-Aryl Carbamoyl
1,4-dihydropyridines contribute as an important class of com-
pounds in medicinal chemistry, leading to several new drugs currently  widely
used especially as calcium channel antagonist1 and other cardiovascular dis-
eases also. .
SYNTHETIC METHODS OF DIHYDROPYRIDINE
B. Chekavichus et.al.,2 has proposed following kind of successive
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The synthesis of 1,4-dihydropyridines involves following steps.
(1) Intermediate (A) involves cyclisation of 3-arylaminocrotonate and arylidene
followed by the rearrangement of hydrogen.
(2) Intermediate (B) involves dehydration of (A) with loss of equimolar quan
tity of water.
(3) Intermediate (C) involves isomerisation of intermediate of (B) and obt
ained regio and stereo selective 1,4-dihydropyridine as a final product.
It has been observed that in the presence of piperidine as a catalyst,
pyran was formed as an intermediate by the cyclocondensation of aliphatic or
aromatic aldehydes with 1,3-diketones, followed by the dehydration of pyran
through the reaction with aliphatic or aromatic amines affored final product.

































         R, R3 = H / Aryl / Aryl

















R, R1= Alkyl / Aryl
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MECHANISM:
The Mechanism of 1,4-dihydropyridine prepared by Hantzsch synthesis
involves three steps can be depicted as follow:



































































(1) Abstraction of proton by base from ethyl acetoacetate to form nucleo
phile.
(2) Attack of nucleophile on alkyl/aryl aldehyde molecule to yield β−keto
ester.
(3) Condensation of NH3 with β−keto ester with removel of water molecule
to give 1,4-dihydropyridine derivative.
Part-I,  Introduction..., “Studies on 1,4-Dihydropyridines”. 17
SYNTHETIC METHODS OF 1,4-DIHYDROPYRIDINES:
Different synthetic methods for the synthesis of 1,4-dihydropyridines
are as follows.
(1) By the condensation of aromatic or aliphatic aldehydes with acetoacet-
icester and aromatic / aliphatic amine in presence of pyridine 3-6.
(2) By the condensat ion of  a l iphat ic or  aromat ic a ldehydes wi th 3-
amino crotonate and 1,3-diketone 2,7-13.
(3) By the condensation of arylidene with 3-aminocrotonate14.
(4) By the condensation of aliphatic or aromatic aldehydes with various
1,3-diketones in presence of ammonia or ammonium carbonate15-17.
(5)       By the condensation of α,β -unsaturated ketones with malononitrile and
cyanoacetamide18.
(6)      By the condensation of o-nitrobenzaldehyde,  β -amino butaricacid
and methylpripiolate in gl. acetic acid19.
(7) By the knoevenagel condensation of benzaldehyde with acetoacetice
ster in presence of β-alanine as catalyst and subsequent
cyclocondensation of the resulting benzylidene with 3-amino crotonate
20.
(8)      By the regio and chemoselective addition of  diphenyl cuprous cyano-
liithium (Ph2Cu(CN)Li2) to substituted N-alkylpyridium salts followed by
acylation of the intermediate21
(9)      By the condensation of 1,3-diketones ,alkyl or aryl aldehydes with aq.
ammonium hydroxide in the presence of piperidine or piperidyl acetate
or potassium acetate or potassium carbonate or gl.acetic acid22-24 .
(10)    By the condensation of two moles of thiobarbituric acid, aromatic-
amines and aromatic aldehydes25-26.
MEDICINAL INTEREST OF 1,4-DIHYDROPYRIDINE
The research on 1,4-dihydropyridine system is of current interest due to
their valuable activities as calcium channel antagonist, vasodilator, cardio-
vascular etc. beside the currently established drugs Nifedipine27-28, Nicardipine29-
30. Many dihydropyridine derivatives have been synthesized world wide31-
33. and have led to numerous second generation commercial product34-
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41such as Nimodipine42-43,Nisodipine44, Nitrendipine45, Amlodopine46,
Felodipine47, Isradipine48, Manidipine49 and Nelvadipine50. Some of their
compounds are characterized by longer bioactivity of greater tissue selectiv-
ity. 1,4-dihydropyridine derivatives are associated with diverse biological ac-
tivities which can be summerised as under.
[A]  Antiarrythemic51 [B]   Antiinflammatory52
[C]  Antiallergic53 [D] Antiulcer54
[E]  Antitumor6 [F] Vasodilator55
[G]  Enzymetic56-57                                  [H]   Calcium channel antagonist 58-60
[I]    Antihypertensive61-62 [J] Antihypolipemic63
[K]  Antimayocardic ischemic64 [L] Cardiovascular65
[M] Photo induced relaxation9,19 [N] Antitubercular agents66
I. Nadeem et.al.,10 (2) have demonstrated the structure activity rela-
tionship of calcium channel and photo induced relaxation of novel 1,4-
dihydropyridines.  Activities of calcium channel antagonists in vitro were









(1) Relative potency order for carbon number four (C-4) phenyl substitu-
ents in ortho and meta position is greater than para position.
(2) Carbon number three(C-3) nitro substitutents decrease calcium chan-
nel antagonist activity.
G. Charles et.al.,68 (3) have synthesized 1,4-dihydropyridines for treat
ment of prostatic hyperplasia.
(2)
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1,4-Dihydropyridine derivatives (3) have been found to be useful in
treai-ng benign prostate hyperplasia inhibition of cholesterol synthesis (4)
show-ed ‘ki’ of 1.9 m.mol/kg in reducing urethral pressure in vivo in dog.
















More recently B. M. Khadikar et.al. ,69  have synthesized 1,4-
dihydropyridine derivatives (5) and tested its antihypertensive activity.
Out of many 1,4-dihydropyridine drugs only Flordipine (6) is N-substi-
tuted derivative that has proved to be very good calcium channel antagonist,
contrary to the belief proposed by D.G.Triggle70 that N-substituted 1,4-
dihydropyridine do not show good antihypertensive activity, probably the con-



















 R1,R2=Methyl / ethyl
 R=Alkyl / Aryl
N-methylnimodipine (7) was found to possess antidepressive70 char-
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parison to control values), which provides excellent example of mechanism of
action similar to that of Flordipine.V. Michael et.al.,72 prepared antihyper-
















A. Daich et.al.,73 have reported calcium antagonist effect of 1,4-
dihydropyridines (9) and M. Suarez et.al.,74 have synthesized calcium an-
tagonist  modulators 1,4-dihydropyridines (10).
R1,R2,R3= methyl / ethyl
X=O, S, N
M.Sharifzadeh et.al.,75have prepared anticonvulsant 1,4-dihyd-
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M. C. R. Franseen et.al.,77 have synthesized 4-substituted-1,4-dihydro-
pyridine-3,5-diesters (13) as Candida rugosa lipase.A.Takahara et.al.,78 have
designed the synthesis of N-type 1,4-dihydropyridines(14)  and reported them
as calcium channel blockers.
A. Motohashi et al.,79 Dihydropyridines with N-phenyl substitution and
tested for tumor specific cytotoxicity and mdr reversal activity to find out the
effects of N-phenyl substitution on activity. Asymmetric 1,4-dihydropyridines
with different substitution on benzoyl aromatic ring were synthesized and
evaluated for tumor specific cytotoxicity. In continuation, dihydropyridines with
phenyl carbamoyl side chain on one arm and –CN, -COOEt, -COOMe side









R = CH3, CH(CH3)2,C6H5,C(CH3)3,

























R = (CH2)2O(CH2)2CH3; R1=Et / Pr / iPr
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V.Burkhardt et., al have synthesized N-acyloxy-1,4- dihydropyridines (17)
and evaluated as p-glycoprotein inhibitors.80
R1= CH3, C2H5 etc..
R2= H,CH3, NO2
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Y.Takshi et.al., have synthesized 1,4-dihydropiridines (20) and reported
as calcium channel blockers.84
R.Budriesi et.al., have synthesized 4-imidazo[2,1-b]thiazol-1,4-
dihydropyridine(21) and reported their cardiodepressant activity85
R1=R2=R3= H,CH3, Cl
Khoshneviszadeh et. al., have synthesized dihydropyridines (22) and





































Part-I,  Introduction..., “Studies on 1,4-Dihydropyridines”. 24
Buelbuel et. al., have synthesized 1,4-dihydropyridines (23),(24) and re-
ported their calcium antagonistic acitivity88
S.R.Pattan et. al., have synthesized 1,4-dihydropyridines(25) and tested
for their anticonvulsant activity 86
In view of procuring highly potent biodynamic agents and after review-
ing literature survey on 1,4-dihydropyridines for their various methods of syn-
thesis and different biological activities, synthesis of 1,4-dihydropyridines have
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SECTION - II:PREPARATION AND BIOLOGICAL EVALUATION OF 4-(5’-CHLO-
 RO-3’-METHYL-1’-PHENYL-PYRAZOL-4’-YL)-2,6-DIMETHYL-/-6-
 ISOPROPYL/2-METHYL-3-CARBMETHOXY/ETHOXY-5-SUBST-
 ITUTED PHENYLCARBAMOYL-1,4-DIHYDRO PYRIDINES.
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SECTION-I
PREPARATION AND BIOLOGICAL EVALUATION OF 4-(5’-CHLORO-3’-ME-
THYL-1’-N-PHENYL-PYRAZOL-4’-YL)-2,6-DIMETHYL/-DIISOPROPYL-3,5-
DISUBSTITUTED PHENYL CARBAMOYL-1,4-DIHYDROPYRIDINES(Ia-t).
1,4-Dihydropyridine derivatives represents one of the most active
classes of compounds possessing wide spectrum of biodynamic activities52-
67. In order to have potent therapeutic agents, the synthesis of 4-(5’-chloro-
3’-methyl- 1’-N-phenyl-pyrazol-4’-yl)-2,6-dimethyl/-isopropyl-3,5-disub-
stituted phenylcarbamoyl-1,4-dihydropyridines (Ia-t)have been undertaken
by the cyclocondensation of  one  mole of 5-chloro-3-methyl-1-N-phenyl-
pyrazole-4-carbaldehyde with two moles of N-(substitutedphenyl)-3-
oxobutanamides/4-methyl 3-oxopetanamides in presence of ammonia.
The constitution of the products (Ia-t)  have been delineated by elemental analy-
ses, IR, PMR and Mass spectral data.
 The products (Ia-t)  were assayed for their in vitro biological assay like
antibacterial activity towards S. pyogens MTCC-443, S. aureus MTCC-96
and P. aeruginosa MTCC-441  (Gram positive) and E. coli MTCC-442 (Gram
negative) bacterial strains and antifungal activity towards Aspergillus niger
MTCC-282 and A. clavatus MTCC-1323 at different concentrations i.e.: 0, 5,
25, 50, 100, 250 (μg/ml) for their MIC (Minimum Inhibitory Concentration) val-
ues. The biological activities of the synthesized compounds(Ia-t)  were com-
pared with standard drugs,viz.,Amplicilline,Chloramphenicol, Ciprofloxa-
cin and Norfloxacin (antibacterial), Greseofluvin, Nystatin (antifungal).
Where R= substituted phenyl and    
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EXPERIMENTAL
PREPARATION AND BIOLOGICAL EVALUATION OF 4-(5’-CHLORO-3’-ME-
THYL-1’-N-PHENYL-PYRAZOL-4’-YL)-2,6-DIMETHYL/-ISOPROPYL-3,5-




(A) (i) Preparationof N-(p-tolyl)-3-oxobutanamide81-82(1b)
The synthesis of  N-(4-methylphenyl)-3-oxobutanamide was  undertaken
according to the literature procedure. Yield :47 %, M.P. :113°C, (Required:C,
69.30%;  H, 6.79%;  N, 7.32% for C11H13NO2, Found : C, 69.28%; H, 6.76
%; N, 7.27 %).
TLC solvent system    Rf1: Ethyl acetate : Hexane       (1.5 : 8.5)  = 0.60
TLC  solvent system   Rf2: Methanol        : Chloroform(0.5 : 9.5)  = 0.48
     (ii)Preparationof 4-methyl-N-(p-tolyl)-3-oxopetanamide81-82 (1l)
The synthesis of 4-methyl-N-(p-tolyl)-3-oxopetanamide was  under-
taken according to the literature procedure.Yield :60 %, M.P. :128°C,
(Required:C, 71.14%;  H,7.75%;  N, 6.38 % for C13H17NO2, Found : C, 71.11
%; H, 7.73 %; N, 6.32 %).
TLC solvent system    Rf1: Ethyl acetate : Hexane       (1.5 : 8.5)  = 0.64
TLC  solvent system   Rf2: Methanol        : Chloroform(0.5 : 9.5)  = 0.52
Similarly, other compounds (1a-t) were synthesized and physical data
are recorded in talble no.1A and 1B
(B) (i) Preparation of 4-(5’-chloro-3’-methyl-1’-N-phenyl-pyrazol-4’-yl)-
2,6-dimethyl-3,5-di-(p-tolyl carbamoyl)-1,4-dihydropyridine(Ib):
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A mixture of N-(p-tolyl)-3-oxobutanamide (1b) (3.82 gm, 0.02 M), 5-
chloro-3-methyl-1-N-phenyl-pyrazole-4-carbaldehyde(2.20 gm, 0.01 M)
and ammonia (5-7ml) in methanol  (20 ml) was heated under reflux condition
for 8 to 10 hrs. The reaction was monitored by TLC. The reaction mixture was
allowed to cool at  room temperature. The solid product  so obtained was
filtered, washed with water, dried and crystallized  from suitable solvent. Yield
: 56%, M.P. :191°C, (Required : C, 69.96 %; H, 5.65 %; N, 12.36 % for
C33H32N5O2Cl, Found : C, 69.92 %; H, 5.63 %; N, 12.31 %).
TLC  solvent system  Rf1 : Ethyl acetate : Hexane       (3.0 : 7.0) = 0.48.
TLC  solvent system  Rf2 : Methanol        : Chloroform(0.5 : 9.5) = 0.49.
Similarly, other compounds (Ia-j)  were synthesized. The physical data
are recorded in Table No.IA
(ii) Preparation of 4-(5’-chloro-3’-methyl-1’-N-phenyl-pyrazol-4’-yl)-
2,6-diisopropyl-3,5-di(p-tolyl carbamoyl)-1,4-dihydropyridine (Il)
A mixture of N-(p-tolyl)-4-methyl 3-oxopetanamide(1l) (4.32gm,
0.02M), 5-chloro-3-methyl-1-N-phenyl-pyrazole-4-carbaldehyde (2.20 gm,
0.01 M) and ammonia (5-7ml) in methanol (20 ml) was heated under reflux
condition for 8 to 10 hrs. The reaction was monitored by TLC. The reaction
mixture was allowed to cool at  room temperature. The solid product  so ob-
tained was filtered, washed with water, dried and crystallized  from sutable
solvent. Yield : 49%, M.P.:141°C,(Required :C, 71.36 %; H, 6.42 %; N, 11.25
% for C37H40ClN5O2,  Found : C, 71.29 %; H, 6.40 %; N, 11.18 %).
TLC  solvent system  Rf1 : Ethyl acetate : Hexane       (3.0 : 7.0) = 0.51.
TLC  solvent system  Rf2 : Methanol        : Chloroform(0.5 : 9.5) = 0.58.
Similarly, other compounds (Ik-t)  were synthesized. The physical data
are recorded in Table No.IB
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(C) Antimicrobial activity of 4-(5’-chloro-3’-methyl-1’-N-phenyl-
pyrazol-4’-yl)-2,6-dimethyl/-isopropyl-3,5-disubstituted phenylcarbam-
oyl-1,4-dihydropyridines (Ia-t).
Antimicrobial activity testing was carried out as described under.The
MIC values of test solution are recorded in Table No. 1a, 1b, 1c, 1d, 1e, and
1f.
Evaluation Techniques :-
# The following conditions must be met for the screening of antimicrobial
activity:
- There should be intimate contcact between the test organisms
and substance to be evaluated.
- Required conditions should be provided for the growth microor
ganisms.
- Conditions should be same through the study.
- Aseptic/sterile environment should be maintained.
Various methods have been used from time to time by several
workers to evaluate the antimicrobial activity. The evalutaion can be done by
the following methods :
- Turbidometric method.
- Agar streak dilution method.
- Serial dilution method.
- Agar diffusion method.
# Following Techniques are used as agar diffusion method:
- Agar cup method.
- Agar ditch method.
- Paper disc method.
We have used the Agar cup mehtod to evaluate the antibacterial activ
ity.
It is one of the non automated in vitro bacterial susceptibility tests.
This classic method yields a zone of inhibition in mm results for the
amount of antimicrobial agents that is needed to inhibit growth of specific
microoganisms. It is carried out in petriplates.
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DETERMINATION OF MINIMAL BACTERICIDAL CONCENTRATIONS BY
AGAR CUP METHOD
MATERIALS AND METHOD:
1. All the Synthesized Drugs were used for antibacterial test proce
dures.





- Known antibacterial drugs control
- All MTCC cultures were tested againts above mentioned known and
unknown drugs.
- Mueller hinton broth was used as nutrient medium to grow and dilute the
drug suspension for the test.
- Inoculum size for the test strain was adjust to 108 Cfu [colony forming
unit] per milliliter by comparing the turbidity.
- Following common standard strains were used for the screening of an
tibacterial and antifungal activities:
The strains were procured from Institute of microbial technology,
chandigarh.
- Escherichia coli [Gram negative] MTCC-442
- Pseudomonas aeruginosa [Gram negative] MTCC-441
- Staphylococcus aureus [Gram Positive] MTCC-96
- Streptococcus pyogenes [Gram Positive] MTCC-443
- Aspergillus niger [Fungus] MTCC-282
- Aspergillus clavatus [Fungus] MTCC-1323
(DMSO) was used as diluents/vehicle to get desired concentration of drugs to
test upon standard bacterial strains.
ANTIBIOTIC ASSAY AS PER BRITISH PHARMOCOPEIAS (B.P.)
[Eur. method 2.7.] The potency of an antibiotic is estimated by comparing the inhibi-
tion of growth of sensitive micro-organisms produced by known concentrations of the
antibiotic being examined and a reference substance.
The reference substances used in the assays are substances whose activity
has been precisely determined with reference to the corresponding international stan-
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dard or international reference preparation.
The assay must be desingned in a way that will permit examination of the valid-
ity of the mathematical model on which the potency equation is based. If a parallel-line
model is chosen, the two log dose-response (or transformed response) lines of the
preparation being examined and the reference preparation must be parallel; they must
be linear over the range of doses used in the calculation. These conditions must be
verified by validity tests for a given probability, usually P = 0.05. Other mathematical
models, such
as the slope ratio model, may be used provided that proof of validity is demonstrated.
Unless otherwise stated in the monograph, the fiducial limit of error (P=0.95) of the
assay for potency are not less than 95 % and not more than 105 % of the estimated
potency.
Carry out the assay by method A or method B unless otherwise speicified in the
monograph.
A. DIFFUSION METHOD
1) Liquefy a medium suitable for the conditions of the assay and
2) Inoculate it at a suitable temperature, for example 48oC to 50oC for vegetative
forms, with a known quantity of a suspension of micro-organisms sensitive to the anti-
biotic being examined such that clearly defined zones of inhibition of suitable diam-
eter are provided with the concentrations of the antibiotic used for the assay.
3) Immediately pour into petri dishes or large rectangular dishes a quantity of the
inoculated medium to form a uniform layer 2 mmm to 5 m thick. Alternatively, the me-
dium may consist of two layers, only the upper layer being inoculated.
4) Store the dishes so that no appreciable growth or death of the micro-organ-
isms occurs before the dishes are used and so that the surface of the medium is dry at
the time of use.
5) Using the solvent and the buffer solution indicated in Table A-1, prepare solu-
tions of the reference substance and of the antibiotic being examined having known
concentrations and presumed to be of equal activity.
6) Apply the solutions to the surface of the medium, for example, in cavities pre-
pared in the agar. The same volume of solution must be added to each cylinder or
cavity. OR
7) Alternatively, use sterile absorbent paper of suitable quality; impregnate the
discs with the solutions of the reference substance or the soulutions of the antibiotic
being examined and place on the surface of the agar.
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8) In order to assess the validity of the assay, use not fever than doses of the
reference substance and three doses of the antibiotic being examined having the same
presumed activity as the doses of the reference substance.
9) It is preferable to use a series of doses in geometric progression. In routine
assays when the linearity of the some system has been demonstrated over an adquate
number of experiments using a three-point assay, a two-point assay may be sufficient,
subject to agreement by the component authority. However, in all cases of dispute,
athree point assay as decribed above must be applied.
10) Arrange the solutions on each petri dish on each rectangular dish according to
a statistically suitable design, except for small petri dishes that cannot accommodate
more than six solutions, arrange the solutions of the antibiotic being examined and the
solutions of the reference substance in an alternate manner to avoid interaction of the
more concentrated solutions.
11) Incubate at a suitable temperature for about 18 hours. A period of diffusion
prior to incubation, usually 1 to 4 hours, at room temperature or at about 4oC, as ap-
propriate, may be used to mininize the effects of the variation in time between the
application of the solutions and to improve the regression slope.
12) Measure the diameters with a precision of at least 0.1 mm or the areas of the
circular inhibition zones with a corresponding precision and calcuate the potency us-
ing appropriate statistical methods.
13) Use in each assay the number of replications per doses sufficient to ensure the
required precision.
14) The assay may be repeated and the results combined statistically to obtain the
required precision and to ascertain whether the potency of the antibiotic being exam-
ined is not less than the minimum required.
# BUFFER SOLUTION
Weight / 1000 ml.
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Result and Discussion:
The products (Ia-t) have been subjected to antibacterial activity towards
S. pyogens MTCC-443, S. aureus MTCC-96 and P. aeruginosa MTCC-441
(Gram positive) and E. coli MTCC-442 (Gram negative) bacterial strains
and antifungal activity towards Aspergillus niger  MTCC-282 and A. clavatus
MTCC-1323 at different concentrations i.e.: 0, 5, 25, 50, 100, 250 (μg/ml) for
their MIC (Minimum Inhibitory Concentration) values.
The biological activities of the synthesized compounds (Ia-t)  were com-
pared with standard drugs,viz.,Amplicilline,Chloramphenicol, Ciprofloxacin
and Norfloxacin (antibacterial), Greseofluvin, Nystatin (antifungal).
The results of antimicrobial activity have been depicted on page no. 47
to 52.
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Type  Vibration  mode
C-H (asym. str., m)
C-H (sym. str., m)
C-H (asym. def., m)
C-H (sym. def., m)
C=C & C-C (str., v)
C-H (i.p. def., m)
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Type  Vibration  mode
C-H (asym. str., m s)
C-H (sym. str., m)
C-H (sym. def., m)
C=C & C-C (str., v)
C-H (i.p. def., m)
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m/z = 443 (B.P)

































m/z = 180 (M+1)
m/z = 138 (M+1)
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SECTION-II




1,4-Dihydropyridine derivatives represents one of the most active classes
of compounds possessing wide spectrum of biodynamic activities52-67. In or-
der to have potent therapeutic agents, the synthesis of 4-(5’-chloro-3’-me-
thyl-1’-N-phenyl-pyrazol-4’-yl)-2,6-dimethyl/6-isopropyl/2-methyl-3-carb-
methoxy/ethoxy- 5-substituted phenylcarbamoyl-1,4-dihydropyridines
(IIa’-n’) have been undertaken by the condensation of  Ethyl/methyl-3-amino
but-2-enoate and  2-[(5’-chloro-3’-methyl-1’-N-phenyl-pyrazol-4’-yl) me-
thylene]-3-oxo-N-phenylbutanamide/ pantanamide in basic media.
The constitution of the products (IIa-n’) have been delineated by elemen-
tal analyses, IR, PMR and  Mass spectral data.
The products (IIa-n’)  were assayed for their in vitro biological assay
like  antibacterial activity towards S. pyogens MTCC-443 , S. aureus MTCC-
96 and P. aeruginosa MTCC-441   (Gram positive) and E. coli MTCC-442
(Gram negative)  bacterial strains and antifungal activity towards Aspergil-
lus niger  MTCC-282  and A. clavatus MTCC-1323  at different concentra-
tions i.e.: 0, 5, 25, 50, 100, 250 (µg/ml) for their MIC (Minimum Inhibitory Con-
centration) values. The biological activities of the synthesized compounds
(IIa-n’)  were compared with standard drugs,viz.  Amoxicillin, Chlorampheni-
col, Ciprofloxacin and Norfloxacin (antibacterial) , Griseofluvin, Nystatin
(antifungal).
   R' = Substituted phenyl
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EXPERIMENTAL







(A) (i) Preparation of 2-[(5’-chloro-3’-methyl-1’-N-phenyl-pyrazol-4’-yl)
methylene]-3oxo-N-p-tolylbutanamide (2b).
A mixture of N-(p-tolyl)-3-oxobutanamide  (1.91gm, 0.01 M), 5-chloro-
3-methyl-1-N-phenyl-pyrazole-4-carbaldehyde  (2.20gm, 0.01 M) in 15 ml
methanol and 3 to 4 drops of piperidine  was stirred at room temperature for
24 hours.The reaction mixture was poured into ice called water. The solid prod-
uct so obtained was filtered, washed with little cold methanol, dried and crys-
tallized from methanol. Yield 66%, M.P . :118°C, (Required:C , 67.17%;  H ,
5.08%;  N , 10.68% for C22H20N3O2Cl, Found : C , 67.20 %; H , 5.06 %; N ,
10.63 %).
TLC solvent system   R f1
: Ethyl acetate : Hexane (9.0 :1.0)  = 0.52.
TLC  solvent system  R f2
: Methanol        : Toluene (1.5 : 8.5) = 0.51.
Similarly, other compounds (2a-t) were synthesized and physical data
are recorded in talble no.2A.
(ii) Preparation of 2-[(5’-chloro-3’-methyl-1’-N-phenyl-pyrazol-4’-
yl)-methylene]-4-methyl-3oxo-N-p-tolylbutanamide (2l).
A mixture of 4-methyl-N-(p-tolyl)-3-oxopetanamide  (2.19 gm, 0.01 M),
5-chloro-3-methyl-1-N-phenyl-pyrazole-4-carbaldehyde  (2.20gm, 0.01 M)
in 15 ml methanol and 3 to 4 drops of piperidine  was stirred at room tem-
56
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perature for 24 hours.The reaction mixture was poured  into called water so
the solid product obtained was filtered and washed with little cold methanol,
dried and crystallized from methanol.  Yield  :56 %, M.P .:108°C, (Required:C ,
68.26%;  H , 5.68%;  N , 9.97% for C24H24N3O2Cl, Found : C , 68.29 %; H ,
5.64 %; N , 9.92 %).
TLC solvent system   R f1
: Ethyl acetate : Hexane (9.0 :1.0)  = 0.50.
TLC  solvent system  R f2
: Methanol        : Toluene (1.5 : 8.5) = 0.53
Similarly, other compounds  (2k-t)  were synthesized. The physical data
are recorded in Table No.2 B .
(B) (i) Preparation of Methyl-3-aminobut-2-enoate.
A mixture of methylacetoacetate  (1.16gm, 0.01 M), ammonia solu-
tion (25%) (2.72 ml, 0.04 mol )  was stirred for 4 hours in ice bath. The solid
product so  obtained was filtered and dried. Yield :  68%, M.P.:45°C,
(Required:C , 52.17%;H , 7.82%;N ,12.17% for C5H9NO2, Found :C , 52.20%;
H , 7.79%; N ,12.20%).
(ii) Preparation of Ethyl-3-aminobut-2-enoate.
A mixture of ethylacetoacetate  (1.30gm, 0.01 M), ammonia solution
(25%) (2.72 ml, 0.04 mol )  was stirred for 6 hours in ice bath. The solid prod-
uct so obtained was filtered it and dried. Yield : 58%, M.P .:35°C, (Required:C,
55.81%;H , 8.52%;N ,10.85 for C6H11NO2, Found :C , 55.75%; H , 8.49%;
N ,10.89%)
(C) (i) Preparation of 4-(5’-chloro-3’-methyl-1’-N-phenyl-pyrazol-4’-yl)-
2,6-dimethyl-3-carbmethoxy-5-(p-tolylcarbamoyl)-1,4-dihydropyridine
(IIb).
A mixture of 2-[(5’-chloro-3’-methyl-1’-N-phenyl-pyrazol-4’-yl) me-
thylene]-3oxo-N-p-toylbutanamide (1.97 gm,0.005 M), methyl-3-aminobut-
2-enoate (0.70gm,0.006 M) and anhydrous potassium carbonate  (1.37gm,
0.01 M) in dimethyl formamide  (15 ml) was heated under reflux for 10 to12
hours.The reaction was monitored by  TLC. The reaction mixture was allowed
to cool at room tempreture. The solid product so obtained was filtered, washed
57
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with water, dried and cystallized from dimethyl formamide. Yield : 39%, M.P .
:139°C, (Required : C , 66.12 %; H , 5.51 %; N , 11.40 % for C27H27N4O3Cl,
Found : C , 66.10%; H , 5.48%; N , 11.35%).
TLC solvent system    Rf1: Ethyl acetate :Hexane        (2.5 : 7.5)  = 0.60.
TLC solvent system    Rf2 : Methanol       :Chloroform (0.5 : 9.5)  =  0.58
(ii) Preparation of 4-(5’-chloro-3’-methyl-1’-N-phenyl-pyrazol-4’-yl)-
6-isopropyl-2-methyl-3-carbmethoxy-5-(p-tolylcarbamoyl)-1,4-dihy-
dropyridine (II l).
A mixture of 2-[(5’-chloro-3’-methyl-1’-N-phenyl-pyrazol-4’-yl) me-
thylene]-4-methyl-3oxo-N-p-tolylbutanamide (2.20 gm,0.005 M), methyl-
3-aminobut-2-enoate  (0.70gm,0.006 M) and anhydrous potassium car-
bonate  (1.37 gm, 0.01 M) in dimethyl formamide  (15 ml) was heated under
reflux for 8 to10 hours.The reaction was monitored by  TLC. The reaction mix-
ture was allowed to cool at room tempreture. The solid product so obtained
was filtered, washed with water, dried and cystallized from dimethyl formamide.
Yield : 38%, M.P . :136°C, (Required : C , 67.05 %; H , 5.97 %; N , 10.78 % for
C29H31N4O3Cl, Found : C , 67.08%; H , 5.94%; N , 10.72%).
TLC solvent system    Rf1
: Ethyl acetate :Hexane        (2.5 : 7.5)  = 0.53.
TLC solvent system    Rf2 
: Methanol       :Chloroform (0.5 : 9.5)  = 0.41
(iii) Preparation of 4-(5’-chloro-3’-methyl-1’-N-phenyl-pyrazol-4’-yl)
-2,6-dimethyl-3-carbethoxy-5-(p-tolylcarbamoyl)-1,4-dihydropyridine
(IIv).
A mixture of 2-[(5’-chloro-3’-methyl-1-N-phenyl-pyrazol-4’-yl)-meth-
ylene]-3oxo-N-p-tolylbutanamide (1.97gm,0.005 M), ethyl-3-aminobut-2-
enoate  (0.78gm,0.006 M) and anhydrous potassium carbonate  (1.37 gm,
0.01 M) in dimethyl formamide  (15 ml) was heated under reflux for 12 to14
hours.The reaction was monitored by  TLC. The reaction mixture was allowed
to cool at room tempreture and poured into cold water. The solid product so
obtained was filtered, washed with water, dried and cystallized from dimethyl
formamide. Yield : 46%, M.P . :152°C, (Required : C , 66.53 %; H , 5.74 %; N ,
58
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11.08 % for C28H29N4O3Cl, Found : C , 66.56%; H , 5.72%; N , 11.02%).
TLC solvent system    Rf1
: Ethyl acetate :Hexane        (2.5 : 7.5)  = 0.58.
TLC solvent system    Rf2 
: Methanol       :Chloroform (0.5 : 9.5)  = 0.48
(iv) Preparation of 4-(5’-chloro-3’-methyl-1’-N-phenyl-pyrazol-4’-yl)
-6-isopropyl-2-methyl-3-carbethoxy-5-(p-tolylcarbamoyl)-1,4-dihydro-
pyridine (IIf’).
A mixture of 2-[(5’-chloro-3’-methyl-1’-N-phenyl-pyrazol-4’-yl)-me-
thylene]-3oxo-N-p-tolylbutanamide (2.20 gm,0.005 M),  ethyl-3-aminobut-
2-enoate. (0.78gm,0.006 M) and anhydrous potassium carbonate  (1.37
gm, 0.01 M) in dimethyl formamide  (15 ml) was heated under reflux for 12
to14 hours.The reaction was monitored by  TLC. The reaction mixture was
allowed to cool at room tempreture and poured into cold water. The solid prod-
uct so obtained was filtered, washed with water, dried and cystallized from
dimethyl formamide. Yield : 43%, M.P. :116°C,(Required : C , 67.54 %; H , 6.19
%; N , 10.50 % for C30H33N4O3Cl, Found : C , 67.56%; H , 6.17%; N , 10.46%).
TLC solvent system    Rf1: Ethyl acetate :Hexane        (2.5 : 7.5)  = 0.60.
TLC solvent system    Rf2 : Methanol       :Chloroform (0.5 : 9.5)  =  0.44
.
Similarly, other compounds  (IIa-n’)  were synthesized. The physical data
are recorded in Table No.IIA,IIB,IIC and IID .
(D) Antimicrobial activity of 4-(5’-chloro-3’-methyl-1’-N-phenyl-pyrazol
-4’-yl)-2,6-dimethyl/6-isopropyl/2-methyl-3-carbmethoxy/ethoxy-5-sub-
stituted phenylcarbamoyl-1,4-dihydropyridines (IIa-n’).
Antimicrobial activity testing was carried out as described in Part-I,
Section-I, page No. 30 to 33. The MIC values of test solution are recorded in
Table No. 2a, 2b,2c..... and 2 l
59
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Result and Discussion:
The products (IIa-n’) have been subjected to antibacterial activity to-
wards S. pyogens MTCC-443, S. aureus MTCC-96 and P. aeruginosa
MTCC-441  (Gram positive) and E. coli MTCC-442 (Gram negative) bac-
terial strains and antifungal activity towards Aspergillus niger  MTCC-282
and A. clavatus MTCC-1323  at different concentrations i.e.: 0, 5, 25, 50, 100,
250 (µg/ml) for their MIC (Minimum Inhibitory Concentration) values.
The biological activities of the synthesized compounds(IIa-n’)  were com-
pared with standard drugs,viz.,Amplicilline,Chloramphenicol, Ciprofloxacin
and Norfloxacin (antibacterial) , Greseofluvin, Nystatin (antifungal).
The results of antimicrobial activity have been depicted on page no. 82
to 94.
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When two benzene nucleus are fused with 2,3 and 5,6 positions of
thiazine is called as phenothiazine. Phenothiazine (26) is also known as
thiodiphenyl amine. The structure and numbering of phenothiazine is given
bellow.
A. Benthsen93has synthesized phenothiazine by the reaction of diphe-
nylamine and sulfur in the presence of catalytic amount of iodine particles
in 1883. The most important application of phenothiazine are as an anthelm-
intic90,91 and insecticidal agents.
          Different methods of  synthesis for some substituted phenothiaz-
ines are as follows.
(a) By the action of diphenylamine with sulfur93.
(b) By the action of diphenylamine with thionyl chloride94,95.
(c) By the action of 2-amino thiophenol with 2,4,6-trinitro chloro ben-
zene in presence of sodium hydroxide solution96.
(d) By the action of 2-amino thiophenol with 2,5-dinitro chloro benzene
in presence of sodium acetate solution97.
(e) By the action of 2-amino-2’-iodo-4-4’-dinitro diphenyl sulphide in
presence of cuprous iodide and sodium carbonate98.
(f) By the action phenothiazine in glacial acetic acid with sodium ni-
trite99.
(g)      By the action of 3-nitro phenothiazine in glacial acetic acid with
hydrogenchloride97.
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(i) By the oxidative cyclisation of 2-amino-4-chloro-3-methyl benzene
thiol with 2-halo/2,6-dibromo/chloro nitro benzene101.
(j) By the reaction of 2-formamido-5’-methoxy-2’-nitro-4-trifluromethyl
diphenyl sulphide in presence of ethanolic sodium hydroxide102.
(k) By the reaction of 3,4-dichloro-2-formamido-2’-nitro-4’-bromo diphe-
nylsulphide in presence of ethanolic potassium hydroxide103.
(l) By the reaction of 4-nitrodiphenylamine-2-sulfinic acid in presence
of dilute sulfuric acid104.
(m) By the reaction of aniline, hydriquinol and sulfur105.
(n) By the reaction of N-(4-methyl phenyl)-[1,3]-benzodioxol-5-amine
with sulfur and iodine in o-dichloro benzene106.
Applications of phenothiazines
Phenothiazine exhibited different types of agrochemical activities
which are described as under.
(a)      Larvicidal activity107
(b)      Fungicidal activity108-110
(c)      Acracidal activity111,112
(d)      Plant growth rgulator 113.
Therapeutic Importance
Phenothiazine derivatives showed a wide range of different types of
therapeutic properties which are as follows.
(a) Antitmicrobial activity119-121  (i)   Sedative activity137
(b) Anthelmintic activity122,123    (j)   Antiinflammatory activity138-141
(c) Bactericidal activity124,125     (k)   Tranquilizers142,143
(d) Antidepressant activity126       (l)  Antipsychotropic activity144,145
(e) Antitumour activity127-130       (m)   Antiviral activity 146,147
(f) Anticancer activity131,132,183  (n)   Antidiabetic activity148
(g) Antitubarcular activity133-135  (o)   Antifungal activity149
(h) Antileprotic activity136          (p)   Antimalarial activity150,151
(r) Lipid peroxidation inhibitors and cytoprotective activity158
(s) Antitrypanosomal activity153
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Phenothiazine derivatives have been reported as a valuable human
medicine in the treatment of parkinson’s disease96
R.K.Rathore et. al.,138 have synthesized phenothiazine derivatives
(27) and (28) reported as tranquilizers.


















               R1,R3 = H, Br                                           R = H, NO2, Cl
               R2 = H, NO2, Cl, COOH
P.J.Rosenthal et. al.,146 have synthesized phenothiazine derivatives
(29), (30) and reported their antimalarial activity.
















                          (29)                                                             (30)
             R  = Cl, F                                                  R =  Cl, F
             R1= H, CH3                                              R1= H, CH3,
             R2= H, CH3, Aryl                                     R1= CH3, Aryl
M.J.Yu et. al., have 148 synthesized phenothiazine derivatives (31),
(32), (33), (34), (35), (36), (37), (38), (39), (40) and reported as lipid
peroxidation inhibitors  and cytoprotective agents.
(28)(27)
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O.F.Ginzburg  et. al.,151 have  synthesized phenothiazine de-
rivatives (42) and  reported as antitumor activity.




z ine(48) ,6-Methyl -5-Oxo-5H-benzo[a]phenothiazine (49) ,5H-
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H, davida. shirley. et., al have synthesized  10-(2’-Amino)-phenylphen-
othiazine.(51),and10-(2‘-γ-Diethyaminopropy1amino)-phenylphenothiazine
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Yu.M.Yutilov et. al., have synthesized 5-[(2-Chlorophenothiazin-10-yl)
carbonyl]-spinaceamine(55)
V.R.Radadiya et.al.,153have synthesized 10-(arylaminomethyl)-3-
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Receenty more than 40 drugs of phenothiazine class are now in clini-
cal use. They are applied as antihistamine, sedative, antiemetic, antipsychotic,
neuroleptic, agents. Since last two decades studies devoted to the phenothi-
azine class of compounds have been stimulated due to their promasing ac-
tivities. Some phenothiazine drugs which are now in clinically uses are given
bellow.
  Promethazine hydrochloride                     Trifluoperazine hydrochloride
   (Histamine H1-receptor antagonist,          (antipsychotic,antiemetic)
     antiemetic)
 Chlorpromazine hydrochloride                 Ethopromazine hydrochloride

























 Triflupromazine hydrochloride                     Methdilazinehydrochloride
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E.M. Haves et al.,156 have synthesized phenothiazine (64), (65) and
reported as antipsychotic agent, which are differ onyl in the oxidation state
of the sulfur atom of the ring 2-substituent.
C. Kaiser et al., 157 have synthesized phenothiazine (66) and reported as
potential antidepressant agent.
























 X = SO2
X = S
X= SO
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S.K. Shrivastava et.al.,160 have synthesized  phenothiazine deriva-
tive (67) and (68) reported as antimicrobial and antiinflammatory agent.
(67) (68)
Ar =substituted phenyl
A.K. Yadav et al., 161 have synthesized phenothiazine (69) and
reported as antimicrobail agent.
V.K. Pandey et.al., 162 have reported phenothiazine (70) , (71) as antiviral
agents.
   (70) (71)
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V.K. Pandey et.al., 163  have synthesized  phenothiazine (72)  and
reported their hypoglycemic activity.
      R, R1 = Substituted phenyl
R. Tilak et.al., 165 have reported phenothiazine derivative (73) as
 antiinflammatory activity .
        (73)
    X = Cl, Br
N. Motohashi et al., 171-174 have synthesized phenothiazine (74), (75)
and reported as  antitumor agent.
 (76)          (77)
R = H, n = 3, R = H, n = 4                          R = H, n = 3, R = H, n = 4
R = Cl, n = 3, R = Cl, n = 4                       R = CF3, n = 3, R = CF3 , n = 4
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V.N. Sharma et al., 178 have synthesized phenothiazine (78) and
eveluated as local anaesthetics
         (78)
X = H, Cl       Y = NHC(CH3)3, N N CH2CH2OH
K.T.Douglas et al., 179 hvae synthesized phenothiazines(79), (80) and
eveluated as antitrypanosomal and antileishmanial agents .
     (79)                     (80)
       R1 = H, Cl, CF3, COCH3, COOH/         R1= H
    CH2OH, CONH2   R = (CH2)3NH2, CH2C(CH3)2N(CH3)2
                                                                           (CH2)3NHCH3, (CH2)3N, (CH2)2NEt2
K. Shanker et al., 179 hvae synthesized phenothiazine (81) and re-
ported  as local anaesthetics .
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N.C. Desai et al., 181  have synthesized phenothiazines (82), (83),
(84) and reported as antimicribial and antitubercular agent .
M. Peter.B. et., al182 have synthesized phenothiazines (85),(86),(87)





















H2COC NH N R
ClO
(84)










 (85)  (86)  (87)
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B.Alessandra et.,al183 have synthesized N-substituted phenothiazine-
es (88) and tested for antitumor activitiy.
R1= substituted phenyl
Trivedi A.R et., al184 have synthesized 2-heterocycle-substituted-
phenothiazines (89) and reported  their antitubercular activity.
R= Substituted phenyl
M.D.Bhanushli et al.,185 have synthesized N-substituted phenothiaz-
ines (90) and reported their antifungal and antibacterial activity.
R=  4-chlorophenyl, 4-chloro-3-fluro phenyl, 4-nitrophenyl,
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Y.S. Sandanandan et., al 186have synthesized substituted 10-H -
phenothiazines (91) and reported their anti inflammatory activity.
(a) R1=R2=R3=H (b) R1=CH3,R2=R3=H
(c) R1=Cl, R2=R3=H (d) R1=H, R2=R3=Cl
(e) R1=OCH3, R2=R3 = H (f) R1=R2=H, R3=OCH3
(g) R1=H, R2=R3=OCH2-O- (h) R1=R2=H, R3=NO2
In view of procuring potent biodynamic agent and after reviewing recent
litrature survey on 10-substituted phenothiazines for their various method of
synthesis and different pharmacological activities, synthesis of phenothiaz-
ines have been under taken which can be summerised in the following section
as under.
SECTION-I: PREPARATION AND BIOLOGICAL EVALUATION OF 7/8/9-
SUBSTITUTED-10-N-[BIS(2-CHLOROETHYL/DIETHYL) -
AMINO]-METHYL-PHENOTHIAZINE-1-CARBOXYLIC ACIDS.
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SECTION - I
PREPARATION AND BIOLOGICAL EVALUATION OF 7/8/9-SUBSTI-
TUTED 10-N-[BIS-(2-CHLOROETHYL/ETHYL)-AMINO]-METHYL-PHENO-
THIZINE-1-CARBOXYLIC ACIDS (IIIa-t).
Recent litrature survey on substituted phenothiazines for their other
applications97-109 and various pharmacological profile110-170 suggest to
structually redesign and synthesize some newer bioactive phenothiazines.
The synthesis of 7/8/9/-substituted10-N-[bis-(2-chloroethyl/ethyl)-amino]
methyl-phenothiazines (IIIa-t) have been under taken by the reaction of 7/8/
9-substituted 1-Carboxy  phenothiazines, formaldehyde and 2-chloro-
N-(2-chloroethyl) ethanamine / diethyl amine in acidic media,  which is
known as Mannich reaction.
The constitution of the products (IIIa-t) have been delineated by elem-
ental analyses, IR, PMR and Mass spectral data
The products (IIIa-t)  were assayed for their in vitro biological assay
like  antibacterial activity towards S. pyogens MTCC-443, S. aureus MTCC-
96 and P. aeruginosa MTCC-441  (Gram positive) and E. coli MTCC-442
(Gram negative) bacterial strains and antifungal activity towards Aspergil-
lus niger  MTCC-282 and A. clavatus MTCC-1323 at different concentra-
tions i.e.: 0, 5, 25, 50, 100, 250 (μg/ml) for their MIC (Minimum Inhibitory Con-
centration) values. The biological activities of the synthesized compounds
(IIIa- t)  were compared with standard drugs,viz., Amplicillin, Chlorampheni-














































  R = o/m/p -CH3, -OCH3 and -NO2
  R1 = -Cl/-H 







(A)  Preparation of 1-Carboxy-4’-methyl diphenylamine(3b).
A mixture of 2-chloro benzoic acid (1.56gm, 0.01M) and p-toludine
(1.07gm, 0.01M) in dimethyl formamide(20ml) was refluxed in presence of
anhydrous potassium carbonate (2gm) and  copper powder (0.20gm) for
two hours using an  oil bath. The mixture was filtered and residue was washed
with 10.0 ml hot dimethyl formamide. The filtrate so obtained was pourd in-
to ice cold water and followed by acidification with 10.0 ml dil. hydrochloric
acid. The precipitated acid was then dried in air and recrystallized from etha-
nol.   Yield : 69%, M.P. : 158°C, (Required : C, 73.92%; H, 5.72%; N, 6.17%
for C14H13NO2, Found : C: 73.87%; H, 5.67%; N, 6.13%)
TLC solvent system    Rf1: Ethyl acetate : Hexane       (2.4 : 7.6)  = 0.59
TLC  solvent system   Rf2: Acetone : Bezene (0.5 : 9.5)  = 0.65
Similarly, other compounds (3a-j) were synthesized. The physical data
are recorded in Table No.3A
(B)     Preparation of 1-Carboxy-7-methyl phenothiazine (3l).
A mixture of 1-carboxy-4’-methyl diphenyl amine (2.27gm, 0.01M),
sulfur powder (0.64gm, 0.02M) and iodine (0.3gm)  in 1,2-dichloro ben-
zene (20ml) was refluxed for five  hours in oil bath. The reaction mixture was
distilled to remove excess solvent. The product so obtained was recrystal-
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lized from toluene. Yield : 58%, M.P. : 96°C, (Required : C, 65.30%; H, 4.27%;
N, 5.44% for C14H11NO2S, Found :C: 65.24%; H, 4.21%; N, 5.36%)
TLC solvent system    Rf1: Ethyl acetate : Hexane       (2.4 : 7.6)  = 0.53
TLC  solvent system   Rf2: Acetone : Bezene (0.5 : 9.5)  = 0.62
Similarly, other compounds (3k-t) were synthesized. The physical data
are recorded in Table No. 3B.
(C) (i)  Preparation of 10-N-[bis-(2-chloroethyl)amino]-methyl-7-me-
thyl-phenothiazine-1-carboxylic acid (IIIb):
A mixture of 1-carboxy-7-methyl phenothiazine (2.57gm, 0.01M),  2-
chloro-N-(2-chloroethyl) ethanamine  hydrochloride (1.78 gm,0.01M) and
formaldehyde (2-3 ml) in 20.0 ml of dioxane was refluxed for 8 to10  hours.
The reaction mixture was cooled and  pourd in to cold water. The product so
obtained was filtered, dried  and crystallized from dioxane.Yield : 49%, M.P.
: 119°C (Required : C, 55.42%; H, 4.86%; N, 6.80% for C19H20Cl2N2O2S,
Found : C: 55.37%; H, 4.77%; N, 6.74%)
TLC solvent system    Rf1: Ethyl acetate : Hexane       (2.4 : 7.6)  = 0.39
TLC  solvent system   Rf2: Acetone : Bezene (0.5 : 9.5)  = 0.51
(ii)Preparation of 10-N-[bis-(ethyl)-amino]-methyl-7-methyl-phen-
othiazine-1-carboxylic acid (IIIl):
A mixture of 1-carboxy-7-methyl phenothiazine (2.57gm, 0.01M),
diethyl amine (1.5 ml, 0.015 M), formaldehyde (2-3 ml) and 4 to 5 drops of
conc. HCl in 20 ml of dixoane was refluxed for 8 to 10 hours. The reaction
mixture was cooled and  pourd in to cold water. The product so obtained was
filtered, dried  and crystallized from dioxane.Yield : 41%, M.P. : 133°C, (Re-
quired : C, 70.27%; H, 6.42%; N, 8.17% for C19H22N2O2S, Found : C:
70.21%; H, 6.35%; N, 8.12%)
TLC solvent system    Rf1: Ethyl acetate : Hexane       (2.4 : 7.6)  = 0.51
TLC  solvent system   Rf2: Acetone : Bezene (0.5 : 9.5)  = 0.48
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(D)   Antimicrobial activity of Substituted 7/8/9-substituted-10-N-[bis-(2-
chloroethyl/ethyl)-amino]-methyl-phenothiazine-1-carboxylic ac-
ids (IIIa-t).
Antimicrobial activity testing was carried out as described in Part-I,
Section-I, page No. 31-34. The MIC values of test solution are recorded in
Table No. 3a, 3b, 3c, 3d, 3e and 3f.
Result and Discussion:
The products (IIIa-t) have been subjected to antibacterial activity towards
S. pyogens MTCC-443, S. aureus MTCC-96 and P. aeruginosa MTCC-441
(Gram positive) and E. coli MTCC-442 (Gram negative) bacterial strains
and antifungal activity towards Aspergillus niger  MTCC-282 and A. clavatus
MTCC-1323 at different concentrations i.e.: 0, 5, 25, 50, 100, 250 (μg/ml) for
their MIC (Minimum Inhibitory Concentration) values.
The biological activities of the synthesized compounds(IIIa-t)  were com-
pared with standard drugs,viz.,Amplicilline,Chloramphenicol, Ciprofloxacin
and Norfloxacin (antibacterial), Greseofluvin, Nystatin (antifungal).
The results of antimicrobial activity have been depicted on page no.
132 to 137.
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IR SPECTRAL STUDY OF 10-N-[BIS-(2-CHLOROETHYL)-AMINO]-ME-
THYL-7-METHYL-PHENOTHIZINE-1-CARBOXYLIC ACID (IIIb):











C-H (asym. str., m s)
C-H (sym. str., m)
C-H (asym. def., m)
C-H (sym. def., m)
C=C & C-C (str., v)
C-H (i.p. def., m)













































IR SPECTRAL STUDY OF 10-N-[BIS-(ETHYL)-AMINO]-METHYL-7-ME-
THYL-PHENOTHIAZINE-1-CARBOXYLIC ACID (IIIl):















































































NMR SPECTRAL STUDY OF 10-N-[BIS-(2-CHLOROETHYL)-AMINO]-
METHYL-7-METHYL-PHENOTHIZINE-1-CARBOXYLIC ACID(IIIb):
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SECTION - II
PREPARATION AND BIOLOGICAL SCREENING OF 7/8/9-SUB-
S T I T U T E D -10-N-[(CARBOXYMETHYL)-SULFANYL]-ACETYL-PHE-
NOTHIAZINE-1-CARBOXYLIC ACIDS (IVa-j).
Recent litrature survey on substituted phenothiazines for their other
applications97-109 and various pharmacological profile110-170 suggest to
structually redesign and synthesize some newer bioactive phenothiazines.
The synthesis of 7/8/9-Substituted-10-N-[(carboxymethyl)-sulfanyl]-acetyl-
phenothiazine-1-carboxylic acids (IVa-j) have been under taken by the re-
action of 7/8/9-Substituted-1-Carboxy  phenothiazines, chloroacetyl chlo-
ride followed by the action of thioglycollic acid in basic media.
The constitution of the products (IVa-j) have been delineated by elemen-
tal analyses, IR, PMR and Mass spectral data.
The products (IVa-j) were assayed for their in vitro biological assay
like  antibacterial activity towards S. pyogens MTCC-443, S. aureus MTCC-
96 and P. aeruginosa MTCC-441  (Gram positive) and E. coli MTCC-442
(Gram negative) bacterial strains and antifungal activity towards Aspergil-
lus niger  MTCC-282 and A. clavatus MTCC-1323 at different concentra-
tions i.e.: 0, 5, 25, 50, 100, 250 (μg/ml) for their MIC (Minimum Inhibitory Con-
centration) values. The biological activities of the synthesized compounds
(IVa-j)  were compared with standard drugs,viz., Amplicillin, Chlorampheni-









(IVa-j) R=H, o//,p-CH3, OCH3, NO2
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EXPERIMENTAL
PREPARATION AND BIOLOGICAL EVALUATION OF 7/8/9-SUB-




(A)  Preparation of 1-Carboxy-4’-methyl diphenylamine.
1-Carboxy-4’-methyl diphenylamine has been prepared according
to procedure  cited in section-I, part-II page no.115
Similarly, other compounds (3a-j) were synthesized. The physical data
are recorded in Table No.3A
(B)     Preparation of 1-Carboxy-7-methyl phenothiazine .
1-Carboxy-7-methyl phenothiazine  has been prepared according
to procedure cited in section-I, part -II  page no115.
Similarly, other compounds (3k-t)  were synthesized. The physical data
are recorded in Table No. 3B.
(C) Preparation of 10-[(carboxymethyl)-sulfanyl]-acetyl-7-methyl-
phenothiazine-1-carboxylic acid (IVb):
A mixture of 1-carboxy-7-methyl phenothiazine (2.70gm, 0.01M),
chloroacetyl chloride (1.2 ml 0.012 M) in 10.0 ml of toluene was stirred at
300C for 10 to 12 hours.and monitored the reaction by TLC. After completion
of the reaction, a solution of thioglycolic acid (0.8 ml 0.012 M) in 5.0 ml of
toluene is added and refluxed the mixture for 5 hours. The reaction was moni-
tored by TLC. After completion of reaction the excess toluene was distilled out
and remaining slurry was treated with hexane. The solid product so obtained
was filtered, dried and crystallized from tlouene.Yield : 38%, M.P. 118°C, (Re-
quired : C, 55.46 %; H, 3.85 %; N, 3.59 % for C18H15NO5S2, Found : C,
55.50%; H, 3.88%; N, 3.56%).
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TLC  solvent system :  Ethyl acetate :Hexane     =   1.0  :  9.0= 0.46
TLC solvent system  :  Acetone         : Bezene     =   8.0  :   1.5= 0.61
(D) Antimicrobial activity of 7/8/9-substituted 10-N-[(carboxymethyl)
-sulanyl]-acetyl-phenothizine-1-carboxylic acids(IVa-j):
Antimicrobial activity testing was carried out as described in Part-I(A),
Section-I, page No. 31 to 34. The MIC values of test solution are recorded in
Table No. 4a, 4b, and 4c.
Result and Discussion:
The products(IVa-j) have been subjected to antibacterial activity towards
S. pyogens MTCC-443, S. aureus MTCC-96 and P. aeruginosa MTCC-441
(Gram positive) and E. coli MTCC-442 (Gram negative) bacterial strains
and antifungal activity towards Aspergillus niger  MTCC-282 and A. clavatus
MTCC-1323 at different concentrations i.e.: 0, 5, 25, 50, 100, 250 (μg/ml) for
their MIC (Minimum Inhibitory Concentration) values.
The biological activities of the synthesized compounds(IVa-j)  were com-
pared with standard drugs,viz.,Amplicilline,Chloramphenicol, Ciprofloxacin
and Norfloxacin (antibacterial), Greseofluvin, Nystatin (antifungal).
The results of antimicrobial activity have been depicted on page no.
147 to 149.
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IR SPECTRA OF 10-N-[(CARBOXYMETHYL)-SULFANYL]-ACETYL-7-ME-
THYL-PHENOTHIAZINE-1-CARBOXYLIC ACID (IVb):











































































NMR SPECTRAL STUDY OF 10-N-[(CARBOXYMETHYL)-SULFANYL]-
ACETYL-7-METHYL-PHENOTHIAZINE-1-CARBOXYLIC ACID (IVb):
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Pyrimidine (92) is a six membered heterocyclic compound consisting





Generally pyrimidine derivatives such as 2-hydroxy-substituted-pyrimidine,
2-mercapto-substituted-pyrimidine and 2-amino-substituted-pyrimidine are
studied. Pyrimidines have been isolated from the nucleic acid hydrolysates.
Pyrimidines are among those molecules that make life possible, have
been some of the building blocks of DNA and RNA. Several analogues of
pyrimidines have been used as compounds that interfere with the synthesis
and functioning of nucleic acids e.g. fluorouracil, which has been used in can-
cer treatment. Also there are some thiouracil derivatives, which produce ad-
verse reduction in susceptible patients and found more potent and less likely
to produce side effects and is being widely used187. There are several other
important groups of pyrimidines with medicinal uses.
Pyrimidine ring carrying various substituents may be built up from two
or three aliphatic fragments by the principle synthesis or by a variety of other
syntheses, which are complimentary rather than alternative to it. An alternative
method of synthesis is the isomerisation or break down of another hetero-
cycles such as    hydration of purine, but such methods are rarely used. Pyrimi-
dine is best  considered as a resonance hybrid to which the uncharged equiva-
lent Kekule structures  (93) and (93a) and charged structures (93b) and (93g)
contributes. The self consistent π (pi) electron densities required for the ground
state of pyrimidine are 0.776, 0.825 and 1.103 for positions 2, 4 and 5 respec-
tively197. Despite considerable localization of π (pi) electrons at nitrogen at-
oms of pyrimidines the ring system is still sufficiently aromatic to possess sub-
stantial stability. This has a great advantage in the primary synthesis of pyrim-
idines.























The first primary synthesis from aliphatic fragments was carried out by
Frankland et.al., in 1848. Since then a many distinct primary synthetic meth-
ods have been devised186,188-191,194,196,199,201,202,205.  It is also pos-
sible to prepare pyrimidines from other heterocyclic compounds such as pyr-
role187,  imidazole189 ,  isoxazole and oxazole193,195,  pyridine203,
pyrazine204, 1,3,5-triazine198, oxazine200, thiazine206 by different pro-
cesses.
SYNTHETIC METHODS FOR PYRIMIDINES
Various methods for synthesis of pyrimidines  which are reported in the
literature are as follows.
(a) By the condensation of urea and malonic acid led to formation of pyrimidine209.
(b) By the condensation of malonic ester and urea led to formation of pyrimidine210.
(c) By the condensation of formamidine with phenylazomalononitrile led to
formation of 4,5,6-triaminopyrimidine208.
(d) By the condensation of aromatic aldehydes,ß-ketoester or substituted
ß-ketoester with urea or thiourea led to formation of pyrimidines207.
(e) By the condensation of thiourea and substituted ß-ketoester in pres
ence of sodium ethoxide led to formation of 2-mercaptopyrimidines211.
(f) By the condensation of chalcones with dicyandiamide in presence of
piperidine led to formation of pyrimidines212.
(g) By thermal or microwave irridiation of thiourea and substituted ß-ketoester
in presence of dimethylformamide led to formation of substituted
tetrahydropyrimidines213.
(h) One pot synthesis of aromatic aldehydes,ß-ketoester or substituted
ß-ketoester with urea or thiourea led to formation of substi tuted
Part-III,  Introduction..., “Studies on pyrimidines”. 155
dihydro pyrimidin-2-ones catalysed by CuCl2214.
(i) One pot synthesis of aromatic aldehydes,ß-ketoester or substituted
ß-ketoester with urea or thiourea led to formation of 3,4-dihydro
pyrimidin-2-(1H)-ones/thiones under microwave irradiation215.
(j) One pot synthesis of aromatic aldehydes,ß-ketoester or substituted
ß-ketoester  wi th  urea or  th iourea led to  format ion of  d ihydro
pyrimidin-2-(1H)- ones catalysed by Tin (II) chloride (SnCl2)215.
(k) One pot synthesis of aromatic aldehydes,ß-ketoester or substituted
ß-ketoester with urea or thiourea led to formation of  3,4-dihydro
pyrimidin-2-(1H)-ones by microwave induced eco-friendly solvent free
biginelli reaction catalysed by calcium chloride216.






























































X = O, S & NH.
The present work is explained by considering basic mechanism of
multicomponents biginelli reaction. This includes the condensation of substi-
tuted benzaldehydes (a) with either urea or thiourea or guanidine to form
hemiaminal (b) with some similarities to the mannich condensation. Hemiaminal
(b) undergoes dehydration in presence of acid catalyst to produce iminium
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cation (c) as a intermediate. The enamine (iminium cation) (c) generated acts
as an electrophile for the nucleophilic addition of keto enol of 4-methyl-oxo-N-
phenylpentanamide with removal of proton to produce (d). The intermediate
(d) undergoes intramolecular condensation in presence of acid between oxy-
gen of ketone and amino group of urea or thiourea or guanidine to give the
cyclised targeted product (e).











































































X = O, S & NH.
This mechanism includes the condensation of pyrazoline aldehydes (a)
with keto-enol of 3-oxo-N-phenylbutanamide (b) to form intermidiate (c) with
some similarities to the aldol condensation. Intermidiate (c) udergoes dehy-
dration in presence of acid catalyst to produce arylidine (d). The condensa-
tion of arylidine (d) with either urea or thiourea or guanidine
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 to form hemiaminal intermidiate (e). Hemiaminal intermidiate (e) undergoes
intramolecular condensation in presence of acid between oxygen of ketone
and amino group of urea or thiourea or guanidine to give cyclised targeted
 product (f).
PHARMACOLOGICAL IMPORTANCE OF PYRIMIDINES
Numerous pyrimidines are well known drugs for variety of diseases. They
may be placed in four categories viz. barbiturates, sulfonamides, antimicrobi-
als and antitumor agents. Uracil, thymine, alloxan, vicine and divicine, cytosine,
chroticacid, willardiline, tetradotoxine, becimethrian (94), blasticidine (95),























(94)          (95)         (96)
Pyrimidine derivatives have wide varieties of usages. Pyrimidine ring
system is also present in Vitamin B2 and folic acid. Pyrimidine ring system
having a mercapto group occupy a unique position in medicinal chemistry.233
These types of derivatives play a vital role in biological processes219-221 as
well as synthetic drugs.218
Some of the therapeutic activities of pyrimidine derivatives can be
summarized as follows.
(a) Antithyroid231,232 (b)      Antitumor224,253-254
(c)      Antihypertensive234,245-246  (d)     Antiinflammatory1244,280-281
(e)      Diuretic223  (f)       Antimalarial225,227,230
(g)      Antispasmodic226  (h)      Anticonvulsant255
(i)       Antineoplastic235,273,333,334(j)       Anthelmintic239
(k)      Antimicrobial222,236-240,247,256-279,331
(l)       Cardiovascular248-250 (m)     Antiviral241,270-273,333
(n)      Platelet aggregation inhibitor228,229
(o)      Antihistamine242,243,332 (p)      Anti-HIV251,282,330
(q) Antitubercular252
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The basis of any rational drug discovery programme is fundamently, the
Medicinal Chemistry. Although the synthesis of modified nucleic acids has been
a subject of interest for some time, the intense focus on the medicinal chemis-
try of oligonucleotides dates perhaps to not more than five years. As a result
of this, the scope of medicinal chemistry has recently been expanded enor-
mously, but the biological data of supporting the conclusions about synthetic
strategies have just begun to emerge.
Modifications in the base, sugar and phosphate moeities of oligonucle-
otides and oligonucleotide conjugates have been reported. The subjects of
medicinal chemical programmes include approaches to create enhanced af-
finity and more selective  affinity for RNA or duplex structures, the ability to
cleave nucleic acid targets, enhanced nuclease stability, cellularuptake and
distribution, in vivo tissue distribution, metabolism and clearance. Although
substantial progress in the    medicinal chemistry of oligonucleotides has been
made in the past three years, it is not yet possible to reach the conclusion
about the therapeutic ability of the novel modifications. Preliminary data on
effects on nuclease stability and hybridization properties for a few modifica-
tions and activity in vitro suggest that the next generation of oligonucleotides
may display substantially improved potencies and   selectivity.
PYRIMIDINE MODIFICATIONS (Nucleotide)
A relatively large number of modified pyrimidines have been synthe-
sized and now incorporated into oligonucleotides and evaluated. The principle
sites of modification are C-2, C-4, C-5 and C-6 (97) .  These and other













sites of pyrimidine Modification
(97)
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In as much as the C2 position is involved in Watson-Crick hybridization,
oligonucleotides containing C2 alkyl modified  pyrimidines have shown unattrac-
tive hybridization characters. However, an oligonucleotide containing 2-thioth-
ymidine (98) was found to hybridize well to DNA and, in fact even better to
RNA with a thermal melting temperature (ΔTm) value of 1.5°C/modification. In
a different study, oligoribonucleotides with 2’-o-methyl-2-thiouridine (99) ex-
hibited a thermal melting temperature (ΔTm) value of +5.5°C/modification
when hybridized against RNA resulting from a highlly preoganized RNA-like
C3’-endo conformation (attributed to the combination of 2-thio modification
and 2’-o-Mesubstituent). Oligonucleotides with this modification also exhibit
better hybridization discrimination for the wobble uracil-guanosine (U-G) base
pair formation compared to the normal uracil-adenine (U-A) base pair. This
selectivity is a result of weaker    hydrogen bonding and increased steric bulk
























In contrast, the pyrimidine modifications in 4-position with interesting
properties have been reported. 4-Thiopyrimidines (100,101) have been incor-
porated into ol igonucleotides with no signif icant negative effect on
hybridization.However,    recent studies have shown destabilization in the nor-
mal uracil-adenine (U-A) base pair formation and stabilization of the wobble
uracil-guanosine (U-G) base pair for 4-thiouridine. A bicyclic and an 4-methoxy
analog of cytosine were shown to hybridize with both purine bases in DNA with
thermal melting temperature (Tm) values approximately equal to that of natu-
ral base pairs.  Additionally, a fluorescent base has been incorporated into
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The pyrimidine modification at C5 position including halogenated
nucleosides have been reported. Although the stability of duplexes may be
enhanced by incorporation 5-halogenated uracil containing nucleosides, the
occasional mispairing with guanidine and the potential that the oligonucleotide
might degrade and release toxic nucleosides analogs cause concern. Oligo-
nucleotides containing 5-propynylpyrimidine (102,103,103) modification have
been shown to enhance the duplex stability thermal melting temperature (ΔTm =
1.6°C/modification ), and support RNase H activity. The 5-heteroaryl-pyrimidines
were also shown to increase the stability of duplexes. A more dramatic influ-
ence was reported for the tricyclic 2’-deoxycytidine analoges, termed
phenoxazine, exhibiting an enhancement of  2-5°C/modification, depending on
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As expected, modifications in the C6 position of pyrimidines are highly
dupled destabilizing. Oligonucleotides containing 6-azapyrimidines (105) have
been shown not only to reduce the  thermal melting temperature (Tm) value by
1-2°C per modification, but also to enhance the nuclease stability of oligonucle-















The increasing interest in the early 1970s in properties and use of inter-
feron (IFN) together with the difficulty in producing useful amounts of interferon
(IFN) led to the search for agents that would induce IFN in the host.
Precedenced at that time for interferon (IFN) inducers included viruses and bacte-
rial wall constituents and entities of large molecular weight such as the poly-
nucleotides. There were also several examples of low molecular weight substances
such as certain antibiotics and the antiviral agent, tilorone.292 In 1976 it was re-
ported that 6-methyl pyrimidinone(2-amino-5-bromo-6-methyl-4-(3H)pyrimidinone,
ABMP) induced circulating levels of interferon (IFN) in several animal specis upon
oral or intraperitoneal administration.287 Subsequent structure-activity studies
yielded a more potent and less toxic 6-phenyl ananlog called ABPP or bropirimine
(2-amino-5-bromo-6-phenyl-4-(3H)pyrimidinone) (figure 1 and Table 1).285,291
Bropirimine and related 6-aryl analogs were examined extensively for efficacy
in virus and tumor models, along with their immunomodulatory properties and
overall pharmacological effects.297


















 Figure 1 : Preliminary SAR of antiviral activity of pyrimidinones
    Table - I
Antiviral Activity
monosubstituted Disubstituted       Heterocyclic
Active         2-F,OMe, Me 3,5-OMe 1-Naphthyl
          3-F,OMe, Cl, NO2 2,5-Cl2 2-Pyrazyl
Me, CF3, MeCH2CH2O, 3,5-OMe 2,3-pyridyl
Br,I 3,4-Cl2 2-Furyl
4-F, Cl 3,5-Cl2
Inactive 4-Me, CN, Butyl, 2,3-OMe 2-Napthyl
OH,OCH2ph, OMe 1-Furyl
4-Pyridyl
                                         2-Quinoline
As with the polynucleotides, the pyrimidinones exhibited significant ac-
tivity against interferon (IFN) sensitive viruses such as Semliki Forest virus in vivo.
However, in addition, they exhibited prophylactic and therapeutic activity upon
either local or systemic administration to rodents infected with a variety of
DNA viruses, such as the herpes viruses (HSV-1, HSV-2 , CMV  and pseudora-
bies), and when administered intranasally for upper respiratory infections, such
as infectious    bovine rhinortacheites, influenza A and para-influenza-3. Par-
ticularly interestion activity was noted  with bropirimine on intravaginal admin-
istration in protection against HSV-2 intravaginal infection in guinea pigs, an
important model for genital herpes in humans.298 Bropirimine also exhibited
activity when given either intraperitoneally or orally to mice infected with Listera
monocytogenes. The efficacy in this model  was not abrogated by the addition
of anti-interferon (IFN)  antibody.293
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PYRIMIDINES AS ANTITUMOUR AGENTS
A number of other pyrimidine antagonists displaying antitumour activ-
ity, in which the base is conjugated to a modified suger ring have been re-
ported. Although D-Arabinofuranosyl uridine (ara-uridine) shows no useful
acitivity,  and 5-bromo- and 5-iodo-D-arabinofuranosyl uridine inhibit the growth
of  sarcoma 180 and L1210 cells in culture.284 Other thymidine analogues with
simi lar  act iv i ty  i n c l u d e  5 - a z i d o m e t h y l - , 5 - a m i n o m e t h y l  a n d  5 -
hydroxymethyl-2’-deoxyu-ridine286. 3’-Amino-3’-deoxy thymidine288 and 3’-
amino-2’,3’-dideoxycy-tidine182 also posses strong activity against L1210 leu-
kaemia 2’-Deoxy-2’-fluoro-5-methyl-1-B-D-arabinofuranosyluracil (FMAU; 40)
is highly active against arabinofuranosyl cytidine (ara-C) resistant L1210 and P815
cell lines both in vitro and in vivo.295 2-B-D-Ribofuranosylthiazole-4-
carboxamide (Tiazofurin; 41) has aroused much interest recently for its activ-
ity against solid tumour such as lung carcinoma. It is metabolized to an ana-
logue of NAD in which the thiazole-4-carboxamide moiety replaces the nicoti-
namide ring. However, it also depresses the synthesis of DNA and RNA, and
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PYRIMIDINES AS ANTI-HIV AGENTS
The strategy of designing nucleoside analogs that are selective for vi-
ral DNA polymerases is the most well-studied and successful approch to
viral chemotherapy, and has led to the discovery of several clinically useful
antiviral drugs. This strategy, however, has inherent limitations. Human DNA
polymerases also required dNTP’s and the chemical mechanisms of polymer-
ization by the viral and human enzymes are similar. Nucleoside analogs often
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have significant host toxicity that is probably related to inhibition of host cell DNA
synthesis. Nevertheless, these compounds constitute the major class of antivi-
ral drugs, and this approach is likely to yield additional active compounds in
the near future. For the long term, however, other strategies may ultimately lead
tonmmore selective agent withn lower toxicity.
Obviously, the key to design analogue with a lower affinity for the host en-
zyme than the viral enzyme, which requires that there be structural differences
between the enzyme active sites. For reverse transcriptase, the most well stud-
ied inhibitor is 3’-azido-3’-deoxythymidine (AZT; 42), which is currently used










3’-azido-3’-deoxythymidine (AZT) inhibits HIV reverse transcriptase with
an IC50 of 40nM300, but is 100-300 times less active against mammalian
DNA polymerase α and DNA polymerase γ. The reason for this selectivity is
not clear since 3’-azido-3’-deoxythymidine (AZT) is a chain terminator for mam-
malian DNA polymerases and inhibits normal cellular DNA synthesis.290 Sev-
eral other dideoxynucleoside analogs have been shown to be potent inhibi-
tors of HIV replication in vitro.301,305 In general, these compounds have the same
mechanism of action as 3’-azido-3’-deoxythymidine (AZT), that is, intracellular
conversion to the triposphate derivative and subsquent inhibition of HIV re-
verse transcriptase.
Some of these compounds are simply analogs of the nautral 2’-deoxy-
nucleoside in which the 3’-OH group has been replaced with a hydrogen, such
as 2’,3’-dideoxycytidine(109), 2’,3’-dideoxyadenosine(110) and 2’,3’-dideo-
xythymidine (111). Other analogs contain a 2’-3’ double bond, such as 2’3’-
didehydro-2’,3’-dideoxythymidine (112). Several related analogs with other
modifications to the ribose ring or the heterocyclic base moiety have also been
reported to have activity against HIV or HIV reverse transcriptase.195,196
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R. A. Nugent et. al.,310 have synthesized pyrimidine thioethers (113)













PYRIMIDINE AS ANTIBIOTICS :
There are few examples of pyrimidine antibiotics. The simplest of all is
bacimethrin (5-hydroxymethyl-2-methoxypyrimidin-4-amine) (114), which is ac-
tive against several staphylococcal infections311. Gourgetin (115), a cytosine
derivative is active against mycobacteria as well as several Gram-positive
and Gram-negative bacteria312. There are more derivatives of cytosine,nam-
ely amicetin (116) and plicacetin (117), which exhibit activity against acid fast
and Gram-positive bacteria as well as some other organisms311.Puromycin
has a wide spectrum of antitrypanosomal activity. Aminogly- coside antibiot-
ics phleomycin , bleomycin  and related families are wide-spectrum antibiot-
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ics containing the pyrimidine ring. Another antibiotic tubercidine is reported
to exhibit antitumour properties312. In addition, they have antineoplastic ac-
tivity. Bleom ycin is already in clinical use against certain tumours like Hodgkin’s
lymphoma and disseminated testicular cancer313.
(114) (115)
(116) (117)
PYRIMIDINE AS ANTIFUNGALS :
Pyrimidines also exhibit antifungal properties. Flucytosine (118)314 is
a fluorinated pyrimidine used as nucleosidal anti fungal agent for the treat-
ment of serious systemic infections caused by susceptible strains of candida
and cryptococcus315.Hexitidine316 (119) is mainly used for the treatment of
aphthous ulceration.
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PYRIMIDINE AS ANTITUBERCULAR:
Capreomycin (120) produced by Streptomyces capreolus is a second-
line bacteriostatic antituberculin drug containing pyrimidine317,318.
(120)
Viomycin (121) is more tuberculostatic than p-aminosalicyclic acid. It is
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PYRIMIDINE AS ANTHELMENTICS :
These drugs have the ability of ridding the body of parasitic worms.
Pyrantel pamoate (122) is a depolarizing neuromuscular blocking agent that
causes spastic paralysis in helminthes and is employed in the treatment of
infestations caused by pinworms and roundworms319.
 (122)
PYRIMIDINE AS ANTIHISTAMINIC :
Taziphylline (123) is ten times more potent than either astemizole or
terfenadine in its affinity for H1-histaminebinding site and appears to be de-
void of CNS activity320.Another pyrimidine containing antihistaminic drug,
temelastine (124a) is comparable to mepyramine321. Radiolabelled studies
have indicated that it does not penetrate the CNS appreciably. Icotidine (124b)
, a structural analogue of temelastine lacks CNS activity and is a dual antago-
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(124a),  R1=Br,  R2 = -CH3
(124b),  R1=H,  R2 = -OCH3
A family of trisubstituted pyrimidines has been described as selective
COX-2 inhibitors. To explore the usefulness of pyrimidine derivatives as po-
tential NSAIDs. Aurelio Orjales et. al.,323 have synthesized novel pyrimidine
derivatives (125) and (126).
In vitro biological evaluation of these compounds has provided infor-














   (125) Y=CH; X=Z=N    (126)  Y=Z=N; X=CH
F. Manetti et. al.,324 have synthesized novel pyrimidines (127) with















R = Ph, Me, CO2Me,     
       CONMe2, CONEt2
(127)
D.Rot i l i  e t  a l . ,325  have synthes ized 6-subst i tu ted- [1- (2 ,6-
difluorophenyl]pyrimidinones (128,129) and tested against endogenous,
nontelomeric reverse transcriptase (endo-RT) in human differentiating cell


















R. Storer et al.,326 have synthesized 3-substituted-6-(3-ethyl-4-
methylanilino)uracils (130,131) screened for their capacity to inhibit the repli-




















(130)   n = 2,3,4. (131) n = 2,3,4.0
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A.Or ja les  e t  a l . ,327  have synthes ized new ser ies  o f  2- (4-
methylsulfonylphenyl)and 2-(4-sulfamoylphenyl)pyrimidines (132) and evalu-









Y.Miyazaki et al.,328 have synthesized 4-amino-5,6-furo [2,3-d] pyrimidines








Recently, S.M.Bhalekar et al.,329 have synthesized cromon pyrimidines
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      H. Takao et al.,335 have synthesized  2-Pyridinecarboxaldehyde [6-
(tert-butyl)thieno[2,3-d]pyrimidine-4-yl]hydrazone derivatives (135) and iden-










M.B.Deshmukh et al.,336 have synthesized 2-amino-5cyano-6-hydroxyl-
4-aryl pyrimidines (136) and reported their antibacterial activity.





    R= -Cl, -NO2, -OCH3, -OH
M.Sharma et al.,337 have synthesized quinolinyl pyrimidines(137) and
evaluated for antitubercular and antimalarial activity.







R= 4-isopropyl phenyl, 3-pyridyl,  4-thiomethyl
(136)
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In view of procuring highly potent biodynamic agents and after review-
ing recent literature survey on oxo / thio / iminopyrimidines for their  various
methods of synthesis and different pharmacological activities, synthesis of py-
rimidines have been undertaken which can be summarized in the following
one section as follows:
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SECTION - III




Keeping in view of wide spectrum biodynamic activit ies 116-174
of pyrimidines and with a view to have potent therapeutic agents, the synthe-
sis of 4-(5’-chloro-3’-methyl-1’-N-phenyl-pyrazol-4’-yl)-6-methyl-2-oxo-/
thio-/imino-5-N-substituted phenyl carbamoyl-1,2,3,4-tetrahydro pyrim-
idines (V a-d’) have been synthesized by the condensation of different  N-sub-
stituted phenyl-2-oxobutanamides, 5-chloro-3-methyl-1-N-phenyl-
pyrazole-4-carbaldehyde , and urea/thiourea/ guanidine  in the presence
of catalytical amount of acid.
The constitution of the products (Va-d’) have been delineated by
elemental analyses, IR, PMR and  Mass spectral data.
The products (Va-d’) were assayed for tfor their in vitro biological as-
say like  antibacterial activity towards S. pyogens MTCC-443 , S. aureus
MTCC-96 and P. aeruginosa MTCC-441   (Gram positive) and E. coli MTCC-
442  (Gram negative) bacterial strains and antifungal activity towards Aspergil-
lus niger  MTCC-282  and A. clavatus MTCC-1323  at different concentra-
tions i.e.: 0, 5, 25, 50, 100, 250 (µg/ml) for their MIC (Minimum Inhibitory Con-
centration) values. The biological activities of the synthesized compounds (Va-
d’)  were compared with standard drugs,viz.,  Amplicillin, Chloramphenicol,












R= Substututed phenyl 
X= O/ S/ NH


























X= O / S / NH
H+
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EXPERIMENTAL
PREPARATION AND BIOLOGICAL EVALUATION OF 4-(5’-CHLORO-3’-
METYL-1’-N-PHENYL-PYRAZOL-4’-YL)-6-METHYL-2-OXO/-THIO/-IMINO-





(A) Preparationof N-(4-methylphenyl)-3-oxobutanamide (1b).
N-(4-methylphenyl)-3-oxobutanamide has been prepared according to
the procedure cited in Part - I, Section - I, Page No.28
(B) (i) Preparation of 4-(5’-chloro-3’-methyl-1’-N-phenyl-pyrazol-4’-yl)-
6-methyl-2-oxo-5-N-(p-tolyl)-1,2,3,4-tetrahydro pyrimidine (V b).
A mixture of N-(4-methyl phenyl)-3-oxobutanamide  (2.22 gm, 0.01M),
5-chloro-3-methyl-1-N-phenyl-pyrazole-4-carbaldehyde (2.20 gm, 0.01
M), urea (0.90 gm, 0.015 M) and catalytic amount of HCl in dimethylformamide
(10 ml)  was heated under reflux condition for 8 to10 hrs. The reaction mixture
was kept at room temperature for 24 hrs. The yellow crystalline product so
obtained was filtered and crystallized from dimethylformamide. Yield : 55 %,
M.P . : 232°C, (Required : C , 63.31%; H , 5.04%; N , 16.05% for C23H22N5ClO2
Found : C , 63.65 %; H , 5.03 %; N , 15.97 %).
TLC  solvent system Rf1
   :  Ethyl acetate : Hexane        (4.0 : 6.0) = 0.57.
TLC  solvent system Rf2  
 :  Methanol        : Chloroform (1.0 : 9.0) = 0.63.
Similarly, other compounds (Va-j) were synthesized. The physical data
are recorded in Table-V A.
Part - III, Section - I..., “ Studies on Pyrimidines.” 177
(ii) Preparation of 4-(5’-chloro-3’-methyl-1’-N-phenyl-pyrazol-4’-yl)-
6-methyl-2-thio-5-N-(p-tolyl)-1,2,3,4-tetrahydro pyrimidine (Vl).
A mixture of N-(4-methylphenyl)-3-oxobutanamide  (2.22 gm, 0.01M),
5-chloro-3-methyl-1-N-phenyl-pyrazole-4-carbaldehyde (2.20 gm, 0.01
M), thiourea  (1.14 gm, 0.015 M) and catalyt ic amount of  HCl in
dimethylformamide (15 ml)  was heated under reflux condition for 10 to12 hrs.
The reaction mixture was kept at room temperature for 24 hrs. The yellow crys-
talline product so obtained was filtered and crystallized from dimethylform-
amide. Yield  : 50 %, M.P. : 224°C, (Required : C , 61.06%; H, 4.86%; N , 15.49%
for C23H22N5ClOS  Found : C , 61.02 %; H , 4.83 %; N , 15.40 %).
TLC  solvent system Rf1
   :  Ethyl acetate : Hexane        (4.0 : 6.0) = 0.47.
TLC  solvent system Rf2  
 :  Methanol        : Chloroform (1.0 : 9.0) = 0.53.
Similarly, other compounds (Vk-t) were synthesized and the physical data are
recorded in Table-V B .
(iii) Preparation of 4-(5’-chloro-3’-methyl-1’-N-phenyl-pyrazol-4’-yl)
-6-methyl-2-imino-5-N-(p-tolyl)-1,2,3,4-tetrahydro pyrimidine (V v).
A mixture of N-(4-methylphenyl)-3-oxobutanamide  (2.22 gm, 0.01M),
5-chloro-3-methyl-1-N-phenyl-pyrazole-4-carbaldehyde (2.20 gm, 0.01
M), guanidinehydrochloride  (1.43 gm, 0.015 M) and catalytic amount of HCl
in dimethylformamide (15 ml)  was heated under reflux condition for 12 to14
hrs. The reaction mixture was kept at room temperature for 24 hrs. The  prod-
uct so obtained was filtered and crystallized from dimethylformamide. Yield :
52 %, M.P. : 244°C, (Required : C , 63.45%; H , 5.28%; N , 19.31% for
C23H23N6ClO Found : C , 63.43 %; H , 5.25 %; N , 19.25 %).
TLC  solvent system Rf1
   :  Ethyl acetate : Hexane        (4.0 : 6.0) = 0.51.
TLC  solvent system Rf2  
 :  Methanol        : Chloroform (1.0 : 9.0) = 0.60.
Similarly, other compounds (Vu-d’) were synthesized and the physical
data are recorded in Table-V C .
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(D) Antimicrobial activity of 4-(5’-chloro-3’-methyl-1’-N-phenyl-
pyrazol-4’-yl)-6-methyl-2-oxo-/thio-/imino-5-N-substituted phenyl-car-
bamoyl-1,2,3,4-tetrahydro pyrimidines (V a-d’):
Antimicrobial activity testing was carried out as described in Part - I,
Section - I, page No. 31-33. The  MIC values of test solution are recorded in
Table No. 5 a, 5b, 5c, 5d, 5e, 5f, 5g, 5h and  5i.
Result and Discussion:
The products(Va-d’) have been subjected to antibacterial activity to-
wards S. pyogens MTCC-443, S. aureus MTCC-96 and P. aeruginosa
MTCC-441  (Gram positive) and E. coli MTCC-442 (Gram negative) bac-
terial strains and antifungal activity towards Aspergillus niger  MTCC-282
and A. clavatus MTCC-1323  at different concentrations i.e.: 0, 5, 25, 50, 100,
250 (µg/ml) for their MIC (Minimum Inhibitory Concentration) values.
The biological activities of the synthesized compounds(Va-d’)  were com-
pared with standard drugs,viz.,Amplicilline,Chloramphenicol, Ciprofloxacin
and Norfloxacin (antibacterial) , Greseofluvin, Nystatin (antifungal).
The results of antimicrobial activity have been depicted on page no.
194  to 202 .
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Type  Vibration  mode
C-H (asym. str., m s)
C-H (sym. str., m)
C-H (asym. def., m)
C-H (sym. def., m)
C-H (str., v)
C=C & C-C (str., v)
C-H (i.p. def., m)
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Type  Vibration  mode
C-H (asym. str., m s)
C-H (sym. str., m)
C-H (asym. def., m)
C-H (sym. def., m)
C-H (str., v)
C=C & C-C (str., v)
C-H (i.p. def., m)
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Type  Vibration  mode
C-H (asym. str., m s)
C-H (sym. str., m)
C-H (asym. def., m)
C-H (sym. def., m)
C-H (str., v)
C=C & C-C (str., v)
C-H (i.p. def., m)
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PMR  SPECTRAL STUDY OF 4-(5’-CHLORO-3’-METYL-1’-N-PHENYL-PY-
RAZOL-4’-YL)-6-METHYL-2-IMINO-5-N-(p-TOLYL)-1,2,3,4-TETRAHYDRO

























































































































































































































































m/z= 243 (M -1)
m/z=227
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